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Recent studies indicate that oscillations between functional states (ex: ictal, post-ictal) in 
epilepsy are due to fluctuations in neuronal network firing patterns.  However, current epilepsy 
models are often limited to non-mechanistically identifying the most likely anti-epileptic drug 
candidates.  Therefore, expanding research to the network level is a promising way to examine 
the mechanisms underlying mental pathologies and possibly assess better ways to treat them.  
Microtechnology, which allows for control of the local microenvironment, is a reliable way to 
study whole networks, but is rarely applied to neurological disease.  The objective of this project 
is to combine microtechnology with standard neuroscience techniques in an effort to create a 
platform for high throughput testing of anti-epileptic drugs.  To achieve this, we create 
“epileptic” neuronal networks in vitro, characterize network morphology and phenotypic 
connectivity, and evaluate network activity modulation due to genetic manipulations related to 
epilepsy.  This project focuses on the gene SCN1a, which codes for the voltage gated sodium 
channel Nav1.1.  Mutations in SCN1a are linked to Generalized Epilepsy with Febrile Seizures 
Plus.  The central hypothesis is that mutations in SCN1a affect activity properties of individual 
neurons, thus impacting recurrent activity in small networks, and that examining these networks 
may provide insight into pathways involved in seizure propagation. 
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1.0  INTRODUCTION 
Studies indicate that the short-term vacillation between normal and abnormal brain function in 
neurological diseases like dementia and epilepsy may result from changes in neuronal network 
activity [1].  With over 600 nervous system disorders affecting 50 million Americans annually, 
research should be expanded to the network level to search for clues on how neurological 
diseases work [2]. 
On average, the human brain contains 100 billion neurons with hundreds of cell types and 
an estimated 100 trillion interconnections [3].  These interconnections are influenced by 
chemical and mechanical signals and appear to play a critical role in brain function [3].  
Unfortunately, the central nervous system’s complexity and compactness, along with some brain 
regions’ unknown connectivity and inaccessibility, makes it difficult to study networks in vivo.  
Additionally, traditional neuroscience methods often focus on single cell activity.  Even though 
single cell data provides valuable information, it does not shed light on how changes in that 
single cell’s activity impact the network as a whole  [4].  While small in vitro networks can be 
created to overcome these limitations, they form random connections which introduce unwanted 
variability from dish to dish.  A possible way around this is to plate cells on patterned surfaces 
with defined size and geometry, thus controlling connectivity while reducing network 
complexity and inaccessibility  [5-7].  The technique of microcontact printing is a common way 
to create patterned substrates for culturing neurons in vitro [5, 8].  By combining the traditionally 
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engineering-based technique of microcontact printing with classical neuroscience methods, we 1) 
evaluate artificially-generated in vitro networks of cultured neurons and 2) evaluate these 
artificial networks as our in vitro model of Generalized Epilepsy with Febrile Seizures Plus, 
Type II - a disease rarely studied in neurons in vitro. 
1.1 EPILEPSY & SCN1A 
1.1.1 Epilepsy Overview 
Worldwide, more than 50 million people are afflicted with epilepsy- a collection of over 40 
disorders marked by a predisposition to recurrent, unpredictable seizures [9] [10].  The strict 
definition of epilepsy is a neurological disorder where abnormal electrical activity in the brain 
causes loss-of-consciousness and seizures [11].  However, the symptoms of epilepsy vary widely 
based on which type of epilepsy a patient has.  Some patients experience absence, or petite mal 
seizures, where they appear inattentive, become unresponsive, and stare off into space for the 
duration of the seizure [12].  Others experience alternating periods of muscle clenching and 
relaxation known as tonic-clonic, or grand mal, seizures [12]. 
Regardless of type, epilepsy is thought to affect 2 to 3 million people in the United States, 
although a recent study from Hesdorffer et al. indicates that as many as 12 million Americans 
run the risk of developing epilepsy in their lifetime due to age or genetic predisposition [13] [14].  
In addition to being at least as prevalent as breast cancer, epilepsy can also be as deadly: up to 
50,000 Americans die of epilepsy-related deaths each year [15].  Epilepsy-related deaths occur 
due to a variety of causes including suicide, since epilepsy patients are 4 to 6 times as likely to 
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develop depression compared to the general public, seizure-related accidents, development of 
status epilepticus (prolonged seizures lasting longer than five minutes), and SUDEP, or sudden 
unexplained death in epilepsy, where otherwise healthy patients die unexpectedly with no 
apparent cause [16] [17] [18] [19]. 
Finally, epilepsy can be contracted at any point in life, is not specific to race or gender, 
and can have either a genetic component or a physical origin (ex: traumatic brain injury) [20].  
Regardless of basis, epilepsies are classified as being either partial or generalized.  Partial 
seizures originate from, and are localized to, a specific area of the brain, while generalized 
seizures propagate throughout both cerebral hemispheres simultaneously. 
1.1.2 Causes & Mechanisms of Epilepsy 
In addition to epilepsy being a collection of chronic seizure disorders as opposed to a single 
disease, there is also no underlying cause for epilepsy.  A variety of factors may cause a normal 
brain network to be disrupted leading to chronic seizure activity (Figure 1).  For instance, 
physical injuries like traumatic brain injury (linked to Post-Traumatic Epilepsy) [21] or ischemic 
stroke (linked to Epilepsy with Cerebrovascular Diseases) can cause a patient to develop chronic 
seizures [22].  Genetic mutations can also disrupt network function.  For example, mutations in 
SCN1a are linked to Generalized Epilepsy with Febrile Seizures Plus, Type II [23] while 
mutations in PRICKLE1 are linked to Progressive Myoclonic Epilepsy with ataxia [24].  
Additionally, abnormal brain development or connectivity with or without a genetic basis can 
lead to chronic seizures as in the case of Juvenile Myoclonic Epilepsy (abnormal thalamo-cortico 
structure) [25] and Temporal Lobe Epilepsy (decreased Default Mode Network connections) 
[26]. 
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Figure 1: Causes of Epilepsy 
 
 
 
Above: Multiple causes underlying epileptogenesis.  Those in red are examined in this project. 
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Figure 2: Mechanisms of Epilepsy 
 
 
 
Above: Examples of mechanisms underlying epileptogenesis.  Those in red are examined in this 
project. 
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In addition to multiple causes underlying epilepsy, there are also a number of 
mechanisms influencing how a network is disrupted (Figure 2).  For example, protein function or 
expression can be modified as can synapse development, network connectivity, and 
neurotransmitter release.  All mechanisms lead to either an overall increase in network excitation 
or an overall decrease in network inhibition, which ultimately makes patients more likely to seize 
spontaneously or following a seizure trigger like fever or flashing lights. 
1.1.3 Epilepsy Therapies: Pharmaceuticals 
Despite epilepsy’s prevalence, it remains one of the least understood chronic disorders in the 
world [27].  While there is no cure, many cases can be controlled with medication or surgery.  
Typically, the first course of treatment involves anti-epileptic drugs (AEDs).  Effective AEDs 
usually work by increasing network inhibition (by increasing GABA levels, for example) or by 
decreasing network excitation (by blocking glutamate release, for example) [28].  About 60% of 
patients achieve seizure-free status on their first or second AED [29].  However, the odds of 
pharmacologically-based seizure cessation drop dramatically with each subsequent AED tried, 
with a less than 4% chance of seizure cessation likely after the second AED [30] [31].  The 
underlying reason why some patients are able to control seizures with AEDs while others with 
the same syndrome are not is not fully known, but variation in individual genetics is thought to 
play a role [32].  Because patients typically need to be slowly introduced to and weaned off of 
AEDs, the time between diagnosis and successful treatment can vary greatly from patient to 
patient, and significantly increases with each failed AED trial [30]. 
In addition to selecting the proper AED, determining an appropriate dosage can be 
complicated.  Because patients have varying degrees of drug tolerance, with some experiencing 
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drug toxicity at low levels and others being able to stand higher doses, “standard” dosages do not 
exist [33].  Therefore, clinicians often slowly adjust dosages over time to balance drug efficacy 
with side effects like dizziness, fatigue, headache, and weight gain or loss.  Patients who are able 
to control seizures for 2-10 years on AEDs are sometimes permitted to stop AED use.  However, 
patients often relapse, typically within two years [29]. 
1.1.4 Epilepsy Therapies: Surgical 
AEDs eliminate seizures in 60-70% of epilepsy patients and reduce seizures in another 20-30%. 
[10] [34].  Patients with unsuccessful or incomplete AED treatment often face more drastic 
surgical options including tissue resections, vagus nerve stimulation, gamma knife surgery, and 
deep brain stimulation are available [34, 35].  Tissue resection and gamma knife surgeries 
selectively remove areas of the brain linked to seizure activity [36, 37].  Stimulation procedures, 
on the other hand, act as pacemakers to regulate brain activity [38, 39].  However, not all 
surgical treatments are available for all patients.  In fact, deep brain stimulation is currently the 
only surgical option available to treat all types of epilepsy [40].  However, safety and efficacy 
results for deep brain stimulation are still inconclusive and the procedure is yet to be approved 
for U.S. patients by the FDA [41, 42].  On the other hand, traditional surgical interventions are 
well established but are often only options for patients with partial epilepsies because 
generalized epilepsies lack well-defined seizure origin sites.  Additionally, patients whose 
seizures originate in eloquent areas of the brain (those that control speech, vision, or motor 
skills), are not considered good surgical candidates.  Therefore, out of the patients who do not 
achieve seizure-free status following AED therapy, less than 10% of adults actually undergo 
surgery [43]. 
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 Unfortunately, even after surgery, many patients require AEDs, albeit at lower doses.  
The combination of surgery and AEDs successfully eliminates seizures in approximately 70% of 
patients whose seizures cannot be controlled by AEDs alone [31].  Another 10% of surgical 
patients experience significant seizure reduction with a surgery/AED combination [31].  
However, surgical long-term success varies.  Although success rates differ based on the type of 
surgery performed, approximately 38% of adults who undergo traditional epilepsy surgeries 
relapse within 5 years, and 53% relapse within 10 years [44].  Similar results are seen in children 
[45].   
 As currently available options fail to give many patients the seizure-free status they so 
desperately crave, continuing effort should be given to developing new drugs and therapies. 
1.1.5 Current Epilepsy Research 
Despite being the most common neurological disease in the world, epilepsy’s public and private 
funding is greatly reduced compared to other neurological disorders [46].  For example, in 2009, 
Alzheimer’s research received an average of $129/patient and multiple sclerosis received an 
average of $280/patient [15].  Epilepsy, which afflicts almost 12 million more patients 
worldwide than Alzheimer’s and M.S. combined, received only $35/patient in funding [15].  Part 
of the underfunding may be because advances in anti-epileptic drugs (AEDs) have made many 
epilepsies manageable, leading to the mistaken belief that all epilepsies can be controlled.  
Additionally, the fact that epilepsy can be deadly is not widely known, and is often not even 
discussed between doctors and their patients [47, 48]. Furthermore, most epileptics are not in a 
constant state of seizure, and many suffer from absence, or staring seizures, as opposed to the 
more obvious grand mals.  This makes epilepsy less visible to the public at large compared to 
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diseases like cancer, Parkinson’s, or muscular dystrophy where patients have apparent signs of 
illness that may garner more public empathy.  Whatever the reason, epilepsy’s comparative 
underfunding means that research into new therapies needs to be cost-conscious. 
In spite of dwindling research funds, the epilepsy community has continued to reassess 
research goals.  In 2000, the White House-initiated conference, “Curing Epilepsy: Focus on the 
Future,” outlined 17 benchmarks for epilepsy research.  Benchmarks fell into three categories: 
1.) creating better therapies with fewer side-effects, 2.) developing methods to prevent epilepsy 
in at-risk individuals, and 3.) understanding the mechanisms behind epileptogenesis [49].  In 
2005 and 2007, the benchmarks were expanded to emphasize a need for the creation and 
validation of new models that could be used to test novel therapies, to identify AEDs that may be 
most effective in treating a given patient, and to determine which patients are likely to 
experience adverse side-effects or develop intractable seizures [50] [51].  As a result, the 
National Institute of Neurological Disorders and Stroke is pushing for reevaluation of current 
epilepsy models and investigation into the feasibility of “personalized therapies,” which test an 
individual patient’s genotype against available treatments to determine which method(s) and 
dose(s) will be most effective with the least side effects. 
In summary, according to NINDS, new epilepsy models should achieve the following 
goals: 
 Be capable of quickly testing multiple therapies (high through-put testing); 
 Have the potential to be used in personalized medicine; 
 Allow for the examination of disease mechanism; 
 Model chronic epilepsy as opposed to acute seizures; 
 Be inexpensive 
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1.1.6 Current Epilepsy Models 
Historically, AED safety and efficacy have been tested using animal models because they allow 
for system wide drug-effects to be monitored.  Mice have long been considered the gold standard 
and a number of transgenic rodent models exist for the most common types of epilepsy.  More 
recently, simpler animals like zebrafish and Drosophila have been introduced as epilepsy models 
because their genome can be quickly and cheaply modified and they allow for high-throughput 
AED testing [52-54]. 
However, not all transgenic animal models of epilepsy demonstrate spontaneous seizures, 
so external stimuli often need to be applied [55].  External stimuli are also used to create acute 
seizure models in healthy animals if a genetic model is not available.  Two of the most 
commonly used external stimuli are electroshock and chemoconvulsants [55] [52].  
Electroconvulsive thresholding (ECT) or maximal electroshock (MES) models involve passing a 
known amount of electrical current through the animal’s head to induce seizures.  Similarly, 
chemoconvulsant models revolve around giving animals convulsant drugs like Metrazol, 
bicuculline, or nicotine [55].  Both ECT/MES and chemoconvulsant models are popular because 
they can be used to inexpensively screen large numbers of drugs, but chemoconvulsants are 
preferred as they tend to give electrical and behavioral results more-similar to those seen in 
humans [55] [52] 
 Regardless of whether a model animal is genetically modified or not, no whole animal 
model allows researchers to examine the mechanisms behind AED cessation of chronic seizures 
in vivo [56].  Additionally, some disagreement exists as to whether an acute seizure in an 
otherwise healthy animal constitutes a valid model of chronic disease, especially when the 
cellular and molecular basis of epileptogenesis cannot be examined [57].  To examine the origin 
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of epilepsy and to complement whole animal studies, in vitro models of epilepsy have been 
developed. 
 The three common in vitro epilepsy models used are slice, primary cell culture, and 
dissociated single cells.  Like all other epilepsy models, these three preparations have individual 
benefits and drawbacks (Table 1).  Slice work provides the most information regarding in vivo 
network connectivity.  Furthermore, tissue can be isolated from genetically modified animals 
which simultaneously provides samples with underlying pathology and all of the normal tissue 
composition present in a whole animal.  However, precise exposure to extracellular solutions like 
AEDs may be limited in slice work because of the bath solutions necessary to keep the slice 
viable [58].  Additionally, acute slices can only be used for a few hours or days [58].  
Dissociated single cells and primary cell cultures are convenient for examining ion channel 
expression and kinetics, which is quite helpful as many epilepsies are linked to ion channel 
defects.  Dissociated single cells, however, often lose their dendritic arbor when they are 
transplanted from in vivo to in vitro culture [52].  Primary cell cultures, like slices, are sensitive 
to their culture conditions and include multiple cell types which may be difficult to identify 
during experimentation.  Additionally, most primary cell cultures used as genetic models of 
epilepsy are not neurons at all but are actually comprised of non-neuronal cells expressing one or 
more neuronal protein.  Thus, there is a significant lack of an in vitro epilepsy model comprised 
of genetically modified primary neuronal cultures. 
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Table 1: Comparison of Current Epilepsy Models [52] 
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1.2 MOLECULAR BIOLOGY & GENETICS 
1.2.1 Cell Culture 
Maintaining in vitro neuronal cultures is a practice that began over a century ago with Roux’s 
1885 embryonic chicken medullary and Harrison’s 1907 frog neural tube explants [59-61].  
While the basic protocol remains the same, many variations have been developed to improve 
individual culture success.  In 1959, Renato Dulbecco modified Eagle’s basal media to create the 
DMEM still commonly used to culture neurons today [62].  DMEM is often supplemented with 
serum, a portion of blood plasma which is high in proteins and growth factors, that helps 
promote glial proliferation.  Glia are thought to be necessary for healthy neuronal development 
because cultures that lack glia appear to develop fewer or less efficient synapses [63].  However, 
glia introduce variability and glial overgrowth is detrimental when patterning cultures because it 
can allow cells to spread out beyond the pattern limits.  To check glial overgrowth, the anti-
metabolic agent cytosine arabinoside (AraC) is often added to media between days in vitro (DIV) 
2 and 10 [64, 65].  Although effective at killing rapidly proliferating cells like glia, AraC can 
negatively impact neurons as well, especially in low-density cultures [66, 67] [68].  In 2004, 
Brewer et al. developed Neurobasal, a modified form of DMEM/F12 specifically designed for 
culturing embryonic hippocampal neurons which made the use of primary neuronal cultures 
more practical for research purposes [69].  Neurobasal has reduced levels of some amino acids 
and lacks serum, thus promoting neuronal development while limiting glial proliferation.  Unlike 
serum supplemented media, B27 supplemented Neurobasal yields cultures composed of less than 
0.5% glia that are viable for over four weeks [69]. 
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A combination of serum positive DMEM and B27/Glutamax supplemented Neurobasal is 
used in this project as it is optimal for culturing nucleofected embryonic rat hippocampal neurons 
[70]. 
1.2.2 Plasmid Generation 
With sequencing of the human genome, came genetic advances in molecular biology.  In 
particular, plasmids- double-stranded, often circular, DNA molecules found in bacteria- became 
a common way to create genetic models of disease.  In genetic engineering, plasmids act as a 
vector for transferring external DNA into host cells.  Vectors are created in a multi-step process 
beginning when a gene of interest is inserted into a plasmid containing an antibody resistant 
gene, a multiple cloning site, and a replication origin. 
Although plasmids can replicate on their own within a host, they lack the ability to 
transfer their DNA to a new host without some form of transfer.  Therefore, once a desired 
plasmid vector is created, it is inserted into competent bacteria that are adept at taking up 
heterogeneous DNA through transformation.  Bacterial transformation was initially discovered in 
1928 by Frederick Griffith using Streptococcus pneumonia [71].  It became a widely used 
molecular cloning technique in the 1970s when Mandel and Higa determined that Escherichia 
coli could be transformed after induction of artificial competence [72].  Inducing artificial 
competence is often achieved using methods like calcium chloride transformation where non-
competent cells are incubated in a cold solution of divalent cations, like calcium chloride, then 
heat shocked.  Although the exact mechanism is unknown, two prevailing theories are that 
divalent cations shield negatively charged DNA allowing it to conjugate onto the cells’ 
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negatively charged surface, or that the sudden change from cold to hot conditions weakens the 
cells’ surface, creating pores for foreign materials to pass through. 
A more recent method of transformation, electroporation, induces competence by briefly 
exposing cells to an electric field which creates holes in the cell membrane allowing foreign 
material like plasmid DNA to enter.  Immediately after the electric field is removed, the holes in 
the cell membrane are repaired preventing cell death.  In the early 2000s, Amaxa developed 
nucleofection - an electroporation method that could be used to transfect previously difficult to 
transfect primary cells like neurons. 
1.2.3 Controlling Gene Expression to Understand the Molecular Mechanisms of Epilepsy 
Although much epilepsy research has been done using chemically or electrically induced 
seizures, nearly 100 genetic animal models of epilepsy have been created in recent years [73].  
While induced epilepsy models are helpful in screening new AEDs, genetic models have helped 
identify other genes, ion channels, and post-synaptic receptors impacted by mutations in human 
epilepsy-related genes [73].  These animals provide a platform for studying the pathology 
underlying chronic seizure disorders, but the complexity of the whole animal can limit 
mechanistic study.  Additionally, transgenic animal models can be expensive and time-
consuming to create [74].  Therefore, in vitro models are used as an alternative for evaluating the 
mechanisms underlying epilepsy [74]. 
Many in vitro models use plasmids to introduce exogenous genes to study the molecular 
basis of epilepsy (note: this project uses plasmids encoding the gene SCN1a and the voltage-
gated sodium channel it codes for, Nav1.1).  In one early study, Sugawara et al transfected a 
human embryonic kidney cell line with a plasmid encoding the alpha subunit of Nav1.1 to study 
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Severe Myoclonic Epilepsy of Infancy (SMEI) [75].  Sugawara’s group observed transfected 
cells had extremely low inward sodium currents during whole-cell patch clamp, indicating a 
sodium channel loss-of-function. 
Similarly, Mantegazza et al co-transfected the human embryonic kidney cell line tsA-20a 
with a fluorescently-tagged human Nav1.1 associated 1 subunit and a plasmid expressing an 
M145T mutation in human Nav1.1 [76].  Cell functionality was examined using whole-cell patch 
clamping.  Again, a reduction in current densities indicated a loss-of-function.  Additionally, 
cells expressing the mutant Nav1.1 channels had slower sodium currents and required less 
electrical stimuli to trigger action potentials. 
Finally, Sugiura et al examined loss-of-function mutations including A1685V (used in 
this project) and A1685D in HEK293 cells [77].  In this case, both A1685V and A1685D cells 
displayed decreased sodium current density compared to cells expressing wild type SCN1a 
regardless of  subunit expression.  However, the presence of the subunit did result in some 
sodium current, indicating that the  subunit may be able to partially counteract some loss-of-
function effects for some mutations.  However, the authors stress that the results need to be re-
examined in neurons. 
Non-neuronal cells expressing neuronal proteins have provided useful information 
regarding a protein of interest, but it is imperative that protein function be examined in neuronal 
cultures so their interplay with other ion channels can be explored.  Non-neuronal models simply 
do not allow researchers to determine if and how other ion channels may compensate for 
epilepsy-related mutations that ultimately influence the disease’s mechanism.  Additionally, non-
neuronal cells do not exhibit the same connectivity seen in neurons. 
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1.3 MICROTECHNOLOGY 
1.3.1 Microcontact Printing 
Microtechnology is defined as any technology performed near the one micron scale.  
Improvements in microtechnology have made studying the relationship between network 
geometry and function possible because surface chemistry can be controlled and uniform 
submicron substrates can be repeatedly created [78] [79].  In addition to controlling surface 
topology, microfabrication can be used to control cell-cell and cell-medium interactions, which is 
useful because the local microenvironment affects cell behavior [68, 79, 80].  In general, 
microtechnology provides researchers with a powerful tool to create precise models for 
examining cells’ interactions with themselves and their environment [81]. 
While there are many microtechniques available, this project uses microcontact printing - 
a method similar to using a rubber ink stamp.  Stamps create patterns by either selectively 
modifying the surface (with polylysine for example) to make certain regions more desirable for 
cell adhesion, or by using a pattern’s geometry to manipulate cell growth as neurons tend to stay 
on larger areas where they can spread as opposed to restricted areas where they may not be able 
to extend processes [82] [83]. 
To begin microcontact printing, a master mold must be made using photolithography, a 
process where a photosensitive resin called a photoresist is applied to a substrate then exposed to 
UV light filtered through a photomask containing the desired pattern (Figure 3).  After the 
substrate is developed to remove excess photoresist, a process similar to developing 
photographic film, only the reverse of the desired pattern remains.  Once a suitable master mold 
has been fabricated, polydimethylsiloxane (PDMS), a silicon-based polymer is poured over top 
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(Figure 4).  As the PDMS cures, in the master, an elastomeric stamp containing the desired 
pattern is produced.  After curing and any necessary post-processing is complete, the stamp is 
ready to be “inked” with the molecule of choice. 
 
 
 
 
 
 
Figure 3: Step-by-step photolithography process 
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Figure 4: Step-by-step process for casting a PDMS stamp 
 
 
 
1.3.2 Controlling Network Geometry 
As microtechnology became more popular in neuroscience, more emphasis was placed on 
determining if and how patterned substrates impact culture composition and development.  
Numerous researchers have explored the link between network geometry and functionality 
(Figure 5) [84]. [78, 85-88].  Various studies have determined that patterned cultures exhibit a 
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strong capacity for self-organization, forming a similar ratio of excitatory and inhibitory neurons 
regardless of pattern size, extending undifferentiated neurons within 24 hours of plating similar 
to unpatterned cultures, forming spontaneous connections with neighboring cells, and displaying 
connections and electrical properties similar to those found in vivo [83, 89-91].  Therefore, 
patterned primary cell cultures appear to reduce the randomness and variability typically seen in 
dissociated in vitro cultures while providing networks with characteristics similar to their in vivo 
counterparts and relatively simple network structures that are accessible to a variety of 
experimental set-ups. 
The pattern used in this project is based on the ring-shaped patterns created by 
Vishwanathan et al (Figure 5, top right) [92].  Vishwanathan created small, ring-shaped 
networks composed of 40 to 60 neurons using microcontact printing.  Networks were incubated 
with calcium sensitive fluorophores, exposed to baths of either HEPES-buffered saline (HBS), 
bicuculline methiodide (BMI), or tetrodotoxin (TTX), and stimulated with single or paired 
electrical pulses.  Time-lapse calcium imaging allowed the activity of the entire ring network to 
be quantified by changes in fluorescence intensity.  While there was no unprovoked activity, 
reverberatory activity, defined as network activity persisting >2 s after the cessation of the input 
stimulus, was observed in several cultures of DIV 10-14 E18-E19 hippocampal rat neurons.  This 
activity, which persisted even after cessation of the external stimulus, could be viewed as an 
example of memory because the network essentially “remembered” the stimulus after it was 
removed. 
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Figure 5. Examples of Constrained Neural Networks 
 
 
 
Top Left: Immunostained patterned DIV 3 hippocampal neurons stained for MAP2 (orange); 
scale bar: 50 m [91] Top Right: MAP2-stained (red) networks of rat hippocampal neurons on 
FITC-tagged polylysine rings (green); blue: Hoechst stained nuclei; scale bar: 50 m [92].  
Middle: SEM of clusters of neurons on 100 m polylysine islands (left); micrograph of clusters 
of neurons on 100 m polylysine islands forming a circular network (right) [90].  Bottom: DIV 7 
unpatterned (left) and patterned (right) neural networks grown on planar microelectrode arrays; 
arrows indicate electrodes.  Red: MAP2 stained processes; scale bar: 50 m [93]. 
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1.4 CALCIUM IMAGING 
1.4.1 Calcium Imaging & Neuronal Activity 
Network activity can be observed directly from time-lapse calcium imaging which infers cellular 
activity from intracellular calcium levels.  To prepare cultures for calcium imaging, cells are 
exposed to fluorescently labeled calcium sensitive dyes and monitored under a microscope.  
Changes in the dye’s fluorescence intensity are then recorded and analyzed over time.  Time 
dependent changes in calcium are used to extrapolate information regarding a cell’s activity 
based on the fact that intracellular calcium levels rise in the soma and axon following an action 
potential. 
The first calcium imaging dyes were derived from the luminescent jellyfish protein, 
aequorin.  Many of today’s dyes, however, are based on work done by Roger Tsien’s group at 
U.C. Berkeley in the 1980s.  In 1985, Tsien synthesized the ratiometric calcium imaging dye 
Fura-2 [94].  Its derivative, Fura-2AM, is used in this project. 
Fura-2AM is a high affinity, ratiometric dye that includes an acetoxymethyl (AM) ester.  
Fura-2 readily binds to free calcium, but does not easily pass through the cell membrane.  The 
addition of an AM group makes the dye more lipophilic, allowing it to more readily enter cells.  
Once inside a cell, esterases hydrolyze the AM ester, allowing the dye to freely bind to calcium 
[95].  When Fura-2 family dyes bind calcium, their absorption wavelength shifts from 380 nm to 
340 nm.  The ratio of 340/380 emissions can then be used to extrapolate intracellular calcium 
levels or to infer cell activity.  Although the fluorophore’s decay time makes it impossible to 
visualize individual action potentials, calcium imaging is exceedingly useful in studying signal 
propagation throughout a network.  Additionally, unlike other calcium sensitive dyes, Fura-2 
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family dyes emit at 510 nm regardless of the surrounding calcium levels.  This feature prevents 
variables like cell thickness or dye concentration from confounding results.  Furthermore, using a 
ratiometric method as opposed to a single-wavelength dye limits the effects of photobleaching 
and dye leakage. 
1.5 SUMMARY 
In summary, epilepsy is a common neurological disease that is rarely studied in neurons in vitro.  
Available cell culture techniques and molecular biology methods allow for dissociated neuronal 
cultures to be transfected with exogenous DNA.  The availability of epilepsy-related plasmids 
makes the creation of an in vitro neuronal epilepsy model quite feasible.  Furthermore, pairing in 
vitro cell culture with microtechnology, specifically microcontact printing, may help reduce the 
variability often seen in dissociated cell cultures.  Additionally, in vitro cultures would allow for 
examination of whole network activity, which plays an important role in seizure propagation.  
Calcium imaging is often used to examine network activity in in vitro cultures and could easily 
be used to study epileptogenesis. 
Therefore, we propose to create and evaluate a potential in vitro epilepsy model that is 
inexpensive, can be used for high-throughput testing of multiple AEDs, can study either chronic 
or acute seizures, and could have future potential in personalized medicine.  Such research would 
fill a significant gap in the epilepsy field.  Additionally, we propose to evaluate the use of 
constrained geometry in reducing in vitro variability in an effort to clearly examine how genetic 
modifications impact network functionality. 
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Specifically, we will focus on the gene SCN1a which is associated with Generalized 
Epilepsy with Febrile Seizures Plus, Type II (GEFS+).  SCN1a and the voltage-gated sodium 
channel it codes for, Nav1.1, has been extensively studied in vivo and in non-neuronal in vitro 
cultures.  To complete this project, we will address the following specific aims: 
1.) Create wild type and mutant SCN1a neuronal cultures. This Aim is focused on 
demonstrating small neuronal networks containing wild type and mutant Nav1.1 ion channels can 
be created in vitro.  Specifically, we propose to generate SCN1a plasmids and use them to 
culture genetically modified neuronal networks via nucleofection. 
2. Characterize the phenotype of small neuronal networks containing wild type or 
mutant SCN1a genes.  The working hypothesis for this aim is that mutations in SCN1a affect 
the electrophysiological properties of individual neurons, but may also affect network 
composition.  The goal of this aim is to characterize network composition including Nav1.1 
expression.  Specifically, we propose to assess if transfection with SCN1a plasmids alters overall 
Nav1.1 expression levels as well as Nav1.1 expression levels and patterns in excitatory, 
inhibitory, and glial cells. 
3.  Perform functional analysis of defined networks. The working hypothesis for this 
aim is that changes in activity due to SCN1a mutations impact network functionality.  
Specifically, the modification of SCN1a subunits should modify the activity properties of 
constrained networks.  We propose to assess the impact of genetic modification on network 
functionality through time-lapse calcium imaging of constrained networks. 
This research is innovative because standard biological approaches for studying genetics 
are rarely combined with microcontact printing to examine neurological disease and because a 
neuron-based in vitro model of epilepsy would fill an obvious need in current epilepsy research. 
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2.0  CREATION OF WILD TYPE AND MUTANT SCN1A NEURONAL CULTURES 
2.1 INTRODUCTION 
This chapter is focused on methods needed to create small in vitro neuronal networks expressing 
wild type and mutant Nav1.1 ion channels.  The foundation for this chapter is that the common 
neurological disease, epilepsy, has a well-documented genetic component.  However, epilepsy-
related genetic mutations are not often studied in vitro in neurons, but instead are examined in 
non-neuronal cells expressing one or more neuronal proteins.  Non-neuronal studies are helpful 
in identifying how a protein of interest may work, but they fail to consider other missing 
neuronal proteins and connections.  Therefore, a clear next step to in vitro epilepsy research is to 
transition from non-neuronal networks to neuronal networks. 
2.1.1 Generalized Epilepsy with Febrile Seizures Plus, Type II & SCN1a 
While there are over 40 types of epilepsy, this project focuses on Generalized Epilepsy with 
Febrile Seizures Plus, Type II (GEFS+).  GEFS+ is a spectrum disorder ranging from mild, 
sporadic seizures with normal mental development to catastrophic Severe Myoclonic Epilepsy of 
Infancy (SMEI), which often presents with ataxia and mental handicap, forcing patients to 
require lifelong care (Figure 6) [96] [97]. 
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GEFS+ can be caused by a variety of genetic mutations, but all of them involve the gene 
SNC1a [98].  SCN1a is a gene located at 2q22-24 that encodes the protein Nav1.1- a voltage-
gated sodium channel  subunit found throughout the central nervous system (Figure 7) [99].  
GEFS+-related SCN1a mutations appear to be either missense or loss-of-function mutations that 
result in a decrease in network inhibition [100].  We focus on mutations in SCN1a because it is 
arguably the most well studied epilepsy-related gene known. 
 
 
 
 
 
 
Figure 6: GEFS+ Spectrum 
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Figure 7: Nav1.1 Protein Diagram 
 
 
Above: Nav1.1- a monomer composed of four homogenous domains (DI-DIV), each containing 
six transmembrane segments.  The DI domain contains several positively charged amino acids 
which act as a voltage sensor.  The four domains associate to form a voltage-gated, sodium 
permeable pore (inset) [101].  Locations of mutations used in this project shown in red. 
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Along with isoforms Nav1.2 and Nav1.6, Nav1.1 is responsible for initiating and 
propagating action potentials throughout the central nervous system of mammals [102].  All 
voltage gated sodium channels alternate between open, closed, and inactive conformations.  
Channels are closed at resting potential and open to allow an influx of sodium ions in response to 
local depolarization.  This causes an increase in intracellular ion concentration and membrane 
potential.  As membrane potential increases, the channel quickly inactivates as the inactivation 
gate binds together. 
Since transmembrane -subunits normally create sodium currents in response to 
depolarization, defects in the genes that encode them can result in altered sodium current.  We 
examine two loss of function mutations: A1685V and L986F, which appear to reduce or 
eliminate sodium channel currents in inhibitory cells, resulting in a lack of network inhibition 
which ultimately makes networks more likely to exhibit seizure activity.  Most SCN1a loss-of-
function mutations lead to Severe Myoclonic Epilepsy of Infancy (SMEI) in humans, as seen 
with the L986F missense mutation [103].  The A1685V mutation, however, has been linked to 
both SMEI and the less extreme GEFS+ (sometimes interchangeably referred to as PEFS+ in 
literature) [23, 103, 104].  
2.1.2 SCN1a/Nav1.1 Studies 
The consequences of an SCN1a loss-of-function (LOF) has been studied in genetically modified 
mice [105] [106] [107].  LOF mice present with little if any sodium currents or action potentials 
in hippocampal GABAergic inhibitory neurons, and reduced sodium currents and low firing rates 
in cerebellar GABAergic Purkinje cells (Figure 8).  This indicates that inhibitory neurons are 
highly reliant on Nav1.1 for proper function.  Interestingly, excitatory pyramidal cells’ sodium 
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currents are not affected indicating that excitatory cells either do not express Nav1.1 or that they 
express other voltage gated sodium channels that can compensate for Nav1.1’s loss.  
Additionally, Yu noted a small up-regulation of Nav1.3 in a subset of hippocampal interneurons.  
As Nav1.3 expression generally wanes as Nav1.1 expression increases, increased Nav1.3 
expression indicated that Nav1.1 was not being expressed and that inhibitory neurons were 
compensating by expressing Nav1.3.  Ogiwara et al later confirmed high levels of Nav1.1 in 
inhibitory neurons via immunocytochemistry. 
Nav1.1 mutations have also been studied in vitro, but rarely in neuronal cultures [102].  
Various Nav1.1 modifications have been examined using HEK 293 cells, xenopus oocytes, and 
TSA201 cells, all transfected to express Nav1.1 [76, 103, 108, 109].  However, these models 
examine Nav1.1 in an isolated setting without the presence of other sodium channels or other 
proteins expressed in the brain, and are therefore, limited as mechanistic models for new drugs. 
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Figure 8: Sodium Current, Membrane Potential, & Sodium Channel Conformation 
 
 
 
Above: a) Sodium current vs. time for normal (blue) and loss-of-function (red) channels.  b) 
Membrane potential vs. time for normal (blue) and loss-of-function (red) channels.  c) Voltage 
gated sodium channel conformation. vs. time.  Stimulation shown by lightning bolts. [110] [111]. 
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2.2 MATERIALS & METHODS 
2.2.1 LB Agar Plates 
In order to introduce the desired DNA into mammalian cells, we used bacteria to propagate the 
plasmid.  In brief, agar plates for bacterial growth were made.  Kanamycin was added to plates 
used to grow SCN1a WT, A1685V, or L986F cultures while ampicillin was added to plates used 
to grow pLL3.74-dsRed.  4% (w/v) LB agar was added to DDW and mixed for 10 minutes 
before being autoclaved.  The sterile solution was then placed in a 55oC water bath for 15 min 
until the flask was cool enough to touch.  After adding any desired antibiotics (1 L 50 mg/mL 
ampicillin per mL agar solution or 2 L of 25 mg/mL kanamycin per mL agar solution), the 
plates were poured and cooled for 20 minutes before being stored upside down at 4oC. 
2.2.2 Culturing Plasmids 
Once agar plates were available, bacterial cultures were developed.  To do so, LB agar plates 
containing the desired antibiotic were warmed, upside down, for two hours prior to streaking.  A 
loopful of slightly thawed transfected bacteria was removed using a sterilized inoculating loop 
and gently streaked over an agar plate.  The plate was allowed to sit for 15 minutes until excess 
liquid was absorbed.  Plates were then stored, inverted, at 30oC for SCN1a plasmids or 37oC for 
pLL3.74-dsRed.  After 24-48 hours, the plates were removed from the incubator, wrapped with 
parafilm, and stored at 4oC or used to create broth cultures for mini- and midi-preparations. 
To prepare mini-prep broths, 3 mL of LB containing the same concentration of antibiotics 
as the LB agar plates, were transferred to a vial.  One small, isolated colony from an agar plate 
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was picked and dropped into the culture vial.  The vial was then loosely sealed and shook at 175 
rpm (at 30oC for SCN1a plasmids or 37oC for pLL3.74-dsRed) overnight until cloudy.   
LB cultures with appropriate antibiotics were then used directly for mini-preps or to 
develop Terrific broth (TB) cultures for midi-preps. 
Original SCN1a plasmid stocks were a kind gift from Dr. Al George, Jr.  Original 
pLL3.74-dsRed stocks were a kind give of the Dr. Luk Van Parijs lab. 
2.2.3 Plasmid Preparations 
A number of plasmids were central to this project including two mutant SCN1a plasmids 
(A158V and L986F), a wild type SCN1a plasmid, and several fluorescent markers (Table 2, 
Figure 9). 
A midi-prep was used to isolate moderate yields of plasmid DNA.  Because the cells 
were EndA+, a guanidine hydrochloride wash was included.  LB cultures were expanded in 
Terrific broth (TB) to improve plasmid yield.  Briefly, 1 L of antibiotic per mL and 750 L of 
cells from an LB starter colony was added to Terrific broth.  After shaking at 240 rpm, 30oC, 
overnight, cells were harvested by centrifuging for 10 minutes at 21oC, 4200 rpm then 
resuspended and processed following the Wizard midiprep protocol (Promega, Madison, WI).  
The final DNA concentration was assayed using the NanoDrop 1000 (Thermo Scientific, 
Waltham, MA) and aliquots were stored at -20oC. 
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Table 2: Plasmid List 
 
 
Plasmid Size (bp) 
SCN1a WT 10451 
SCN1a A1685V 10451 
SCN1a L986F 10451 
pLL3.74-dsRed 7650 
Pmax-GFP 3486 
m-Cherry 4381 
 
 
 
 
 
 
Figure 9. Plasmid map of SCN1a 
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2.2.4 Assaying DNA Concentration 
Once DNA was prepared, the concentration was assayed using 1 L of sample and the 
NanoDrop 1000 (sterile DDW was used for a blank for all samples).  DNA concentrations were 
also assayed after endotoxin-free ethanol precipitation.  Samples with an A260/A280 value below 
1.8 were discarded as they were not pure enough for nucleofection. 
2.2.5 Endotoxin Removal & Ethanol Precipitation 
Prior to nucleofection, DNA was cleaned to remove endotoxins which are common in plasmid 
DNA preparations.  The following protocol (repeated once per sample) and UltraClean 
Endotoxin Removal Kit were used (MO Biolabs, Carlsbad, CA).  1/10 volume of Endotoxin 
Removal Reagent was added to the DNA sample, vortexed until the solution was homogenous, 
incubated on ice for 5 minutes, and heated at 65oC for 10 minutes.  The solution was then 
centrifuged for 5 minutes at 4oC and the clear aqueous phase was transferred to a new tube using 
endotoxin-free pipette tips.  The final DNA solution was then centrifuged for 5 minutes at 4oC.   
Following endotoxin removal, DNA samples were concentrated using an endotoxin-free 
ethanol precipitation, as ethanol removes hydration shells around DNA molecules, allowing 
more concentrated DNA solutions to form.  1/10 volume of endotoxin-free 5M sodium chloride 
was added to the DNA and mixed followed by two volumes of endotoxin-free EtOH.  The DNA 
was then incubated on ice for 30 minutes and centrifuged for 15 minutes at 4oC.  After discarding 
the supernatant, the DNA pellet was washed with 1 mL of 70% endotoxin-free EtOH, inverted to 
mix, and centrifuged again for 5 minutes at 4oC.  The supernatant was discarded and the pellet 
was allowed to dry in a laminar flow hood for 15-30 minutes before being resuspended in 
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endotoxin-free water.  The new DNA concentration was assayed using a NanoDrop 1000 and 
DNA aliquots were stored at -20oC until needed. 
2.2.6 Restriction Digest 
Prior to gel electrophoresis, plasmids were linearized using restriction digest.  SCN1aWT, 
A1685V, and L986F samples were digested using HindIII with NEB2 and BSA (New England 
BioLabs, Ipswitch, MA).  PLL3.74-dsRed samples were digested using Sal1 with NEB2 buffer 
and BSA (New England Biolabs, Ipswitch, MA).  All components were vortexed before 1-2 g 
of DNA, 100x BSA, and NEB buffer were added to a microtube.  DDW was added to a final 
volume of 20 L followed by 0.2 L enzyme.  The solution was flicked to mix, then spun to 
collect, and incubated overnight at 37oC. 
2.2.7 Gel Electrophoresis 
DNA size was analyzed using a 1.2% polyacrylamide gel and an electrical field.  1x TAE and 
agarose were added to a flask and heated until clear.  The solution was then cooled to 57oC 
before 1.5 L EtBr was added to the gel.  The agarose solution was quickly poured into a tray 
with combs and allowed to solidify for 20 minutes.  After removing the combs, and orientating 
the wells, 1x TAE buffer was added until the gel was submerged and all wells were covered.  10 
L of sample containing 2 L of 5x loading buffer was added per well then 1.5 L of EtBr was 
added to the loading buffer opposite the loading wells.  A 1 kb GeneRuler DNA ladder (Thermo 
Scientific, Pittsburgh, PA) was run in each gel to assess DNA size.  The gel was run for 45 
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minutes at 115 V before being visualized under UV light using GelDoc software (Bio Rad, 
Hercules, CA). 
2.2.8 DNA Sequencing 
Plasmid DNA was sequenced at the University of Pittsburgh Genomics and Proteomics Core 
Laboratories using Sanger sequencing and T3 primer.  Following sequencing, a BLAST search 
was performed on the resultant sequence to verify the plasmid encoding SCN1a. 
2.2.9 Neuronal Harvest, Plating, and Culture 
All experiments were performed using E18-E19 rat hippocampal neurons isolated from freshly 
harvested tissue.  However, some supplemental cultures were obtained from Brain Bits (Brain 
Bits, LLC, Springfield, IL) or from harvested hippocampal tissue stored in Hibernate-E media 
supplemented with 2% B27 and 0.5 mM glutamax (Life Technologies, Grand Island, NY) for 1-
2 days. 
E18-E19 rat pups were sacrificed in accordance with University of Pittsburgh IACUC 
guidelines.  The hippocampal tissue was dissected and dissociated in Hepes-buffered, Ca2+/Mg2+-
free Hank’s BSS before being plated onto coverslips.  To do so, a timed pregnant female was 
euthanized via carbon dioxide asphyxiation and cervical dislocation.  All embryos were collected 
and decapitated.  After removing the scalp and skull, the brain was isolated using forceps.  The 
cortex was then isolated from the midbrain and olfactory bulbs, the dura was removed, and the 
cortical lobes were separated.  The cortex was then trimmed leaving behind the hippocampus and 
a small portion of the surrounding cortex.  The tissue was rinsed with HBSS and digested using 
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trypsin-EDTA.  After incubating for 15 minutes and being rinsed with HBSS, the tissue was 
dissociated using a combination of DNAse and firepolished Pasteur pipettes (one smoothed 
pipette, one reduced to half the original diameter, and one reduced to one third the original 
diameter).  The cells were then spun down (10 min, 4oC, 1800 rpm), counted using Trypan blue 
and a cell cytometer, and diluted to the desired density.  In this case, a final density of 1x105 
cells/mL was desired.  However, cells were plated at 1.67x105 cells/mL to account for 
nucleofection related cell death, which is documented at around 40% [70].  Plating media was 
composed of 96% Neurobasal, 2% B27 (50x), 1% pen-strep, 0.25% 200 mM glutamate, and 
0.125% 10 mM glutamate in 10 mM HCl.   
2.2.10 Nucleofection 
Nucleofection was used to introduce plasmid DNA into neuronal cultures.  For this project, the 
Rat Neuron Nucleofector Kit (Lonza, Walkersville, MD) was used immediately after cells were 
dissociated.  Briefly, cells were counted and 1-6 x 106 cells were aliquoted for transfection 
(typically 4 x106cells were used).  Aliquots were spun at 10g for 5 minutes at room temperature.  
The supernatant was then discarded and cell pellets were resuspended in 100 L of nucleofection 
solution.  1-3 g of DNA was added to the cell solution and briefly flicked to mix.  A fluorescent 
marker (pLL3.74-dsRed, GAP43-RFP, Pmax-GFP, or m-cherry) was added to each SCN1a 
sample as a transfection marker.  The cell solution was then transferred to a certified 
nucleofection cuvette and exposed to program O-03 on the Amaxa Nucleofection Device (Lonza, 
Walkersville, MD).  500 L of warmed RPMI media (Life Technologies, Grand Island, NY) was 
added to the cuvette and cells were immediately transferred to a 1.5 mL microtube and placed in 
a 37oC, 5% CO2 incubator for 5 minutes to allow cells to recover.  The desired quantity of cells 
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was then added to a microtube containing nucleofection media (DMEM + 10% fetal bovine 
serum + 10 g/mL pen-strep) before being transferred to a dish containing stamped coverslips 
and plating media.  After 2-4 hours in an incubator, 25% of the media was exchanged with a 
reduced serum media (DMEM + 5% fetal bovine serum + 10 g/ml pen-strep).  After 24 hours, 
75% of the media was exchanged with plating media (outlined in 2.2.9) to remove nucleospheres 
and preserve patterning.  To limit glial proliferation, one quarter of media was exchanged with 
AraC positive feeding media at DIV 4 and, as needed, after DIV 11 (96% Neurobasal, 2% B27 
(50x), 1% pen-strep, and 0.25% 200 mM glutamine, 5 M final concentration AraC). 
2.2.11 Transfection Efficiency and Co-Transfection Efficiency Calculations 
In order to assess the uniformity of transfection for two plasmids at once, cells were transfected 
simultaneously with equal DNA masses of m-Cherry and Pmax-GFP.  On DIV 7, cells were 
fixed in 4% PFA for 10 minutes, rinsed in PBS three times (5 minutes each), and mounted with 
Vectasheild with DAPI (Vector Labs, Burlingame, CA).  Transfection efficiency for each 
individual plasmid was then assessed along with co-transfection efficiency using a Leica DMI 
4000B fluorescent microscope (Leica Microsystems, Buffalo Grove, IL). 
Additionally, the transfection efficiency of pLL3.74-dsRed was assessed for all cultures 
on DIV 4, 8, and 12.  Results were reported as the mean ± standard error of the mean.  Statistical 
differences between days was assessed per genotype using a 1-way ANOVA and post-hoc 
Scheffe test [112]. 
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2.3 RESULTS 
This chapter focused on the generation of SCN1a plasmids, the transfection of rat hippocampal 
neurons, and the culturing of small networks of control and transfected cells.  The results of these 
experiments are outlined below. 
To assess the success of plasmid generation, gel electrophoresis and DNA sequencing 
was used.  Restriction digest of pLL3.74-dsRed plasmid resulted in 3 bands between 2000 and 
2500 bp (Fig. 10).  Anticipated results were 3 bands at 2137, 2514, and 2955 bp for pLL3.74-
dsRed, indicating successful generation of pLL3.74-dsRed.  Restriction digest of SCN1a 
plasmids resulted in 1 band between 5000-6000 bp, 1 band around 3500 bp, and 1 band near 
2000 bp (Figure 10).  Anticipated results were 3 bands at 1089, 3533, and 5810 bp for SCN1a, 
indicating successful generation of SCN1a WT, A1685V, and L986F plasmids.  Additionally, 
following sequencing, a BLAST search resulted in a 98-99% identity and 0% gap with 
BC172767.1 for SCN1aWT, A1685V, and L986F plasmids.  BC172767.1 is a synthetic 
construct of homo sapien SCN1a.  Gel electrophoresis and BLAST search results combined 
indicate that the plasmids were indeed SCN1a variants. 
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Figure 10: Gel Electrophoresis of Digested and Undigested Plasmids 
 
 
 
Above: agarose gel displaying undigested (uncut) and digested (cut) plasmids. 
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To confirm that multiple plasmids could be co-transfected with close to 100% co-
expression, Pmax-GFP and m-cherry were co-transfected into neurons (Figure 11).  Co-
transfection efficiency was determined to be 89% ± 3, coinciding with co-transfection 
efficiencies seen by other researchers [113].  Additionally, 94% ± 3 of GFP+ cells expressed m-
cherry and 94% ± 5 of m-cherry+ cells expressed GFP.  This confirms the long-accepted theory 
that the presence of one co-transfected plasmid is also indicative of the other’s presence. 
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Figure 11: Co-Transfection Efficiency 
 
 
 
Above: Left: DIV 7 co-transfection efficiency for neurons transfected with Pmax-GFP and m-
cherry. Yellow: total GFP/m-cherry co-expression, Green: % of Pmax-GFP+ neurons also 
expressing m-cherry, Red: m-cherry+ cells also expressing Pmax-GFP. Error bars indicate 
standard error of the mean.  Right: examples of Pmax-GFP/m-cherry co-expression (green: 
Pmax-GFP, red: m-cherry). 
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Cultures were maintained for approximately two weeks and transfection efficiency was 
examined at DIV 4 (Figure 12a), 8 (Figure 12b), and 12 (Figure 12c).  Significance was 
evaluated using a 1-way ANOVA and post-hoc Scheffe test.  Transfection efficiency was 
compared across days for individual genotypes and across genotypes on a given day (Figure 12).  
In general, we observed slightly lower transfection efficiencies for SCN1a-pLL-3.74-dsRed vs. 
Pmax-mCherry, possibly due to the larger plasmid size.  Average transfection efficiencies were 
76% ± 2 overall on DIV 4, 75% ± 2 on DIV 8, and 62% ± 2 overall on DIV 12.  These 
transfection values are in line with those expected by Amaxa [70], although other researchers 
have reported a wide range of transfection efficiencies from <10% to more than 90% [114-117].  
This variability is likely due to differences in culturing and transfection techniques.  There was 
no significant difference in transfection efficiencies across genotypes and transfection 
efficiencies were fairly stable over time.  pLL3.74-dsRed and L986F cells displayed transfection 
efficiencies that did not significantly change over time.  However, SCN1a WT cells displayed a 
significant drop in transfection efficiency from DIV 4 to 12 (p value: 0.035).  Similarly, A1685V 
cultures displayed a significant loss of transfection efficiency from DIV 4 to 12 and DIV 8 to 12 
(p values: 0.00 and 0.004 respectively).  This may be due general cell death and/or because the 
transfection began to become unstable by DIV 12 as the nucleofection kit used for these studies 
only provides stable gene expression for 12-14 days [70]. 
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Figure 12: Transfection Efficiency in Neurons 
 
 
 
Above: Left: Transfection efficiency for pLL3.47-dsRed in neuronal cultures across time 12 ± 
standard error.  Statistically significant differences across days, within the same genotype is 
represented by * and ** (p <0.05 or p <0.01 respectively), as determined by 1-way ANOVA and 
post-hoc Scheffe test.  Right: representative images of pLL3.74-dsRed expression on DIV4 (a), 
DIV8 (b), and DIV12 (c) (blue: nuclei, red: pLL3.74-Red). DIV 4, 8, and 12 n: pLL3.74-dsRed 
(n=12, 11, 11), SCN1a WT (n=10, 10, 12), SCN1a A1685V (n=12, 12, 12), SCN1a L986F 
(n=11, 10, 12). 
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2.4 DISCUSSION 
In general, we demonstrated the successful creation of SCN1a plasmids as well as the ability to 
transfect and culture neurons for at least two weeks.  Additionally, we were able to achieve 
transfection efficiencies near 75% for all genotypes through DIV 8- greatly exceeding the 5-30% 
transfection efficiency generally obtained when transfecting neurons using other techniques like 
calcium phosphate precipitation or lipofection [118].  Furthermore, our nucleofection method 
displayed co-localization of nearly 95% for co-transfected plasmids, confirming that the presence 
of one co-transfected plasmid is indicative of the other in this preparation. 
Overall, plasmid generation was fairly straightforward.  The A1685V (mild) mutant 
proved much easier to generate than the more severe L986F mutant which took several attempts.  
Additionally, observational data also indicated differences between genotypes as some issues 
arose regarding transfected cell viability early on.  Early transfected cultures were maintained 
using only serum-free Neurobasal in an effort to minimize glial expression.  Un-transfected 
(negative control) cells tolerated this protocol well, being easily maintained for up to three 
weeks.  Cells transfected only with fluorescent markers like Pmax-GFP or dsRed-PLL3.74 and 
those expressing SCN1a WT or A1685V showed reduced viability (10-12 day culture length) in 
a serum-free environment, most likely a residual effect of the harsh transfection conditions.  
L986F transfected cultures, however, presented with the lowest cell viability initially with 
cultures rarely surviving past one week.  The decreased viability with reduced serum may 
indicate that nucleofected cells, especially those expressing severe mutations, may rely more 
heavily on glial support.  When the other extreme of all serum media was used, checking glial 
proliferation became difficult and transfected cultures were often overtaken by glia.  This may be 
because the transfection method resulted in increased cell death early on thus increasing the 
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initial glial population, because the transfected cells were more sensitive to AraC and thus more 
likely to die after exposure at DIV 4-7 or, because the mutations, which may impact network 
functionality or composition, made the cultures more delicate and less viable.  However, once a 
combination of serum+ media for the first 48 hours followed by serum-free media for the 
remainder of culture life was implemented, L986F cultures were easily maintained for 2-3 
weeks.  This culture method was well-tolerated for remaining genotypes as well. 
Lastly, nucleofection provided a repeatable way to co-express plasmids across genotypes, 
although the method’s stability beginning at DIV 12 does currently limit the length of 
experiments.  While this preparation may be best for examining the early stages of disease, 
modifications like the use of viral vectors could allow for an extension of experiment length. 
2.5 CONCLUSIONS 
In summary, this chapter served as an important building block for the rest of the project as it 
allowed us to develop genetically modified neuronal networks that could be evaluated for use in 
epilepsy research.  One downside, however, is that because the cultures are already expressing 
native SCN1a/Nav1.1 (and will continue to do so to some extent depending on transfection 
efficiency), assessing levels of native to mutant SCN1a/Nav1.1 is problematic.  Therefore, we 
relied on phenotypical and functional activity to assess the transfections impact. 
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3.0  PHENOTYPIC CHARACTERIZATION OF SMALL NEURONAL NETWORKS 
CONTAINING WILD TYPE OR MUTANT SCNA1 GENES 
3.1 INTRODUCTION 
Changes in genetic makeup often modify protein expression or function.  In loss-of-function 
situations, affected proteins may be expressed but have altered function or the affected protein 
may be expressed at lower levels, both leading to changes in network composition.  Neural 
plasticity allows the brain to adapt to network changes over time, so it is possible that a dynamic 
system like the brain could attempt to compensate for smaller scale changes in network activity, 
as a result of modified protein function.  To that end, this chapter focuses on examining whether 
Nav1.1 expression levels are modified in SCN1a mutant cultures and whether Nav1.1 expression 
patterns vary, suggesting a compensatory mechanism may be reshaping the network.  The 
working hypothesis for this study is that mutations in SCN1a affect the functional properties of 
individual neurons and, therefore, may affect the composition of the network comprised of those 
neurons.  Additionally, forced expression of SCN1a may alter expression patterns of Nav1.1, so 
neuronal phenotypes should be evaluated.  To test this hypothesis, we evaluate patterns of 
connectivity through Nav1.1 co-localization with parvalbumin (largely expressed in inhibitory 
interneurons), vesicular glutamate transporter 1 (an excitatory cell marker), and the microtubule 
associated proteins MAP2 and Tau1 (dendritic and axonal markers, respectively). 
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3.1.1 Nav1.1 Expression 
Wild type Nav1.1 is a 260 kDa transmembrane protein expressed mainly in neuronal cell bodies 
and proximal processes in human brains [119]  In the human hippocampus, Nav1.1 appears to be 
present in the dentate hilus, stratum granulosum, and subicular complex of the hippocampus and 
is “readily detected” in CA2 and CA3 pyramidal neurons [119].  In rodents, Nav1.1 has long 
been thought to be expressed in the soma and dendrites of excitatory and inhibitory neurons 
[120].  Prior work in our lab using the SCN1a plasmids from this project indicated that Nav1.1 
was largely expressed in the soma of visual cortex neurons [121].  More recent studies have 
provided conflicting results regarding Nav1.1 expression.  Gong et al determined that Nav1.1 
expression was prominent in the rat hippocampus, with most expression occurring in somas but 
some expression occurring in pyramidal cell dendrites [122].  However, Duflocq et al indicated 
that Nav1.1 is predominantly expressed in the AIS and Nodes of Ranvier in various regions of 
the mouse hippocampus [123].  They observed that most Nav1.1
+ cells appeared to be 
interneurons except in CA3 where it is expressed by a few pyramidal cells.  Similarly, Ogiwara 
et al examined Nav1.1 expression in mouse cortex and hippocampus and indicated that Nav1.1 is 
predominantly expressed in the axon initial segment of parvalbumin positive (PV+) interneurons 
in the cortex as well as the soma and axons of PV+ interneurons in the hippocampus, with 
extremely low levels of expression in excitatory cells [124] [107].  Other studies indicate that 
approximately 4% of rat pyramidal cell layer neurons in CA3 also express Nav1.1 in proximal 
portions of the AIS [125].  Additionally, cultured rat glia have demonstrated Nav1.1 expression 
along with two other voltage-gated sodium channel isoforms, Nav1.5 and Nav1.6 [126].  Nav1.1 
over-expression in glia is thought to possibly play a role in spreading seizure activity throughout 
the cortex [127]. 
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Parvalbumin (PV) is a calcium-binding protein involved in calcium signaling.  In the 
hippocampus, PV is primarily expressed by GABAergic interneurons, specifically those 
targeting pyramidal cells [128].  Most PV+ interneurons are fast-spiking and responsible for 
providing network inhibition.  Changes in parvalbumin expression have been linked to 
neurological disorders.  Loss-of-function mutation in a PV+ cell’s voltage-gated sodium channel 
would likely reduce network inhibition, and therefore increase overall excitability, and possibly 
cause seizure-like activity.  Previous studies have shown that a 20% reduction in network 
inhibition can lead to overwhelming synchronized cortical activity, and even a small reduction in 
inhibition can generate bursting behavior [129]. 
Vesicular glutamate transporter 1 (Vglut1) is the main vesicular glutamate transporter in 
the human hippocampus [130].  Pyramidal neurons and granule cells in CA1, 2, and 3 show 
strong Vglut1 expression and although glia do not appear to express Vglut1 in vivo, co-
localization has been observed in vitro [131, 132].  In rats, Vglut1 is largely expressed in the 
hippocampus, thalamus, cortex, and cerebellum [133]. 
In summary, this chapter focuses on evaluating how modifying the genotype of some 
cells in a network affect protein expression in the network as a whole.  In part, we are interested 
in any compensatory methods that may be at work to counteract a reduction in overall inhibition, 
but we are also examining if forced expression of Nav1.1 leads to modified protein localization 
within the cell.  To date, studies indicate that Nav1.1 is localized to the soma and dendrites of 
excitatory cells, the axon initial segment of parvalbumin expressing inhibitory cells, and the 
soma of glia.  Additionally, Nav1.1 is thought to have higher expression levels in inhibitory vs. 
excitatory cells. 
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3.2 MATERIALS & METHODS 
3.2.1 Immunocytochemistry 
Cellular phenotype was evaluated using immunocytochemistry and a variety of primary and 
secondary antibodies (Table 3 & Table 4).  Fresh paraformaldehyde solution was prepared by 
combining 76% (v/v) warm DDW, 4% (w/v) paraformaldehyde, and enough 10N NaOH to clear 
the solution. Next, 10% (v/v) 10x PBS, 0.5% (v/v) 1 M MgCl2, 2% (v/v) 0.5 M EDTA, and 4% 
(w/v) sucrose were added and the solution was mixed on an orbital until clear.  NaOH and glacial 
HCl were added until a pH of 7.4 was achieved.  Cells were fixed for 10 minutes at room 
temperature in pre-warmed PFA then washed in PBS three times, 5 minutes each.  Next, cells 
were permeabilized in a 0.3% Triton-X100 solution for 10 minutes and washed three more times 
in PBS, 5 minutes each.  Cells were then blocked in a 5% BSA and 5% GSA solution for one 
hour.  After blocking, coverslips were transferred to parafilm containing 1o antibodies diluted in 
1% BSA and incubated for one hour at room temperature (see below).  Following another PBS 
wash (3 times, 5 minutes each), coverslips were transferred to parafilm containing 2o antibodies 
diluted in 1% BSA (see below).  Samples were incubated in the dark for one hour at room 
temperature before being washed with PBS (3 times, 5 minutes each) and DDW (5 times) to 
remove excess salt.  After excess water was removed, samples were placed on microscope slides 
containing Vectasheild with DAPI and allowed to air dry in the dark for 20 minutes before being 
sealed with nail polish, imaged, and stored in the dark at 4oC. 
To ensure non-specific binding did not occur, the following controls were performed 
prior to experimentation: 
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1.) Negative Primary Antibody: Samples were fixed and stained as outlined, but the 
primary antibody was replaced with 5% GSA/5% BSA. 
2.)  Double-staining Negative Secondary Antibody:  All double staining samples were 
exposed to one primary antibody and the other secondary that would be present. 
 
 
 
Table 3: ICC Primary Antibodies List 
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Table 4: ICC Secondary Antibodies List 
 
 
 
 
 
 
3.2.2 Epifluorescence Imaging 
Immunocytochemistry samples were imaged using a Leica DMI 4000B upright microscope with 
Leica EL6000 and CTR4000 light sources, Leica DFC 350FX camera, and LAS software.  
Images were taken under 40x objective using the following filter cubes: A 11513872 (blue), L5 
11513880 (green), N2.1 11513882 (red), and Y5 11513888 (far red).  Prior to imaging 
experimental samples, imaging settings were determined using control samples.  Once optimal 
settings were determined, they were recorded and maintained for all remaining samples from that 
trial.  Additionally, in order to reduce bleed-through, sequential images were taken beginning 
with far red, then red, green, and blue. 
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3.2.3 Image Analysis & Statistics 
Images collected with LAS software were imported and analyzed using ImageJ v.1.47 (NIH, 
Bethesda, MD).  To assess co-localization, the JACoP ImageJ plug-in was used to calculate the 
Mander’s co-localization co-efficient [112].  For overall Nav1.1, parvalbumin, and Vglut1 
expression, co-localization was defined as the percentage of nuclei (blue) expressing each 
specific protein (far red).  For Nav1.1 co-localization with MAP2, Tau1, PV, or Vglut1, co-
localization was defined as the percentage of Nav1.1
+ regions (green) expressing each specific 
protein (far red).  In both cases, the entire field of view was used because it was comparable in 
cell count to ring-network studies being performed sequentially and we wanted to examine 
similar sized networks.  Previous studies examining morphology and function of patterned vs. 
unpatterned networks indicate no significant differences [78].  Therefore, the expression patterns 
seen in unconstrained networks of similar size and cell density should translate to patterned 
networks.  Statistical analysis was performed using a 1-way ANOVA and post-hoc Scheffe test 
in SPSS v. 22 (IBM, Armonk, NY). 
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3.3 RESULTS 
This chapter focused on examining phenotypic changes introduced by genetic manipulation.  In 
vitro cultures were successfully transfected with SCN1a plasmids and culture composition was 
examined by evaluating overall Nav1.1 (Figure 13, Figure 14, Figure 15), parvalbumin (Figure 
16, Figure 17, Figure 18), and Vglut1 (Figure 19, Figure 20, Figure 21) expression.  
Additionally, Nav1.1 localization was evaluated for several criteria related to its potential 
function in the network.  The first was cellular localization (where is Nav1.1 being expressed in 
the cell) followed by cell-type localization (which cells are expressing Nav1.1).  To assess 
cellular localization, Nav1.1 co-localization with the somato-dendritic marker MAP2 (Figure 22 
& Figure 24) and the axonal marker Tau1 (Figure 23 & Figure 24) was examined.  To assess 
cell-type localization, Nav1.1 co-localization with PV (an inhibitory cell marker) and Vglut1 (an 
excitatory cell marker) was evaluated (Figure 25, Figure 26, Figure 27 & Figure 28, Figure 29, 
Figure 30 respectively). 
All studies involved immunocytochemistry with multiple primary and secondary 
antibodies.  Because auto-fluorescence and non-specific staining are common issues in double-
labeling situations, we took precautions to address these potential pitfalls prior to 
experimentation.  Negative primary tests were performed where both secondary antibodies were 
present but the primary antibodies were replaced with blocking solution.  These samples did not 
auto-fluoresce and did not show non-specific binding for any secondary antibody combination 
tried.  Primary antibodies were also paired with the opposite secondary antibody to ensure there 
was no non-specific binding between the two.  Again, no non-specific binding was observed. 
Additionally, every experimental trial was accompanied with single primary antibody controls.  
For these samples, only one of the two primary antibodies being examined was present along 
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with both secondary antibodies allowing us to evaluate any non-specific or background 
fluorescence for solutions used in that staining trial.  These samples were also used to determine 
imaging settings for that set of experimental trials. 
Nav1.1 expression was evaluated for individual genotypes over time (Figure 14) as well 
as across genotypes on a given day (Figure 15).  Significance was evaluated using a 1-way 
ANOVA and post-hoc Scheffe test.  In all instances, Nav1.1 was expressed by both neurons and 
glia, largely in the soma but with some localization to the axon initial segment in neurons Figure 
13).  Nav1.1 expression varied somewhat over time for individual genotypes.  pLL3.74-dsRed 
cells showed a significant increase in endogenous Nav1.1 expression from DIV 4-12 (45% ± 4 to 
65% ± 5, p = 0.026; Figure 14b).  Negative control cells displayed a similar trend (Figure 14 a) 
as did A1685V cells (Figure 14c).  However, A1685V had significantly higher Nav1.1 expression 
from DIV 4 to 8 (35% ± 4 to 59% ± 3, p = 0.001) and 8 to 12 (35% ± 4 to 59% ± 4, p= 0.002) 
while the changes in negative control cells were more subtle.  SCN1a WT cells, on the other 
hand, displayed a significant decrease in Nav1.1 expression from DIV 8 to 12 (58% ± 3 to 39% ± 
4, p = 0.012; Figure 14c), possibly indicating some compensation for forced Nav1.1 
overexpression.  L986F cells displayed a similar trend over time (Figure 14e).  This drop in 
Nav1.1 expression could be due to gradual cell death as the culture nears DIV 14 or a result of 
the transfection losing stability. 
Nav1.1 expression was also fairly consistent across genotypes on DIV 4, 8, and 12 
(Figure 15).  On DIV 4, negative control cells displayed a significant increase in Nav1.1 
expression compared to A1685V (54% ± 5 to 36% ± 4, p = 0.044; Figure 15a).  However, by 
DIV 8, an average of 57% of all cells expressed Nav1.1 regardless of genotype (Figure 15b).  
This could indicate that a subset of A1685V are compensating for the LOF mutation by up-
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regulating Nav1.1 expression, but that the process takes time.  By DIV 12, however, Nav1.1 
expression appeared sporadic (Figure 15c).  Both SCN1a WT and L986F cells’ Nav1.1 levels 
were significantly lower than pLL3.74-dsRed (39% ± 4.06 and 39% ± 4 vs. 65% ± 5; p values of 
0.002, 0.003, respectively) and negative control cells (39% ± 4 and 39% ± 4 vs. 67% ± 4; p = 
0.011, and p = 0.014 respectively).  This may be due to cell death as the cultures neared the two 
week mark, changes in cell proliferation, transfection transience as nucleofection is only stable 
for 12-14 days, or a combination of the three. 
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Figure 13: Representative Images of Nav1.1 Expression 
 
 
Above: Representative images of Nav1.1 expression.  A) Negative control cells (DIV 12), b) 
pLL3.74-dsRed cells (DIV 12), c) SCN1a WT cells (DIV 8), d) SCN1a A1685V (DIV 8), e) 
SCN1a L986F cells (DIV 8). Arrows indicate neuronal expression.  * indicates glial expression.  
DAPI: nuclei (blue), Alexa 488: Nav1.1 (green). 
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Figure 14: Nav1.1 Expression Over Time for Individual Genotypes 
 
 
Above: Average Nav1.1 expression for individual genotypes on DIV 4, 8, and 12 ± standard 
error.  **: p<0.01; *: 0.01 < p < 0.05 as determined by 1-way ANOVA and post-hoc Scheffe test. 
a) Negative control cells (n=8, 12, 11), b) pLL3.74-dsRed cells (n=9, 9, 8), c) SCN1a WT (n=6, 
9, 8), d) SCN1a A1685V (n=10, 9, 9), e) SCN1a L986F (n=9, 10, 7) 
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Figure 15: Nav1.1 Expression Across Genotypes at a Given Age 
 
 
 
Above: Nav1.1 expression across genotypes on DIV 4, 8, and 12 ± standard error. * and ** 
represent significant differences from transfected controls (pLL3.74-dsRed).  **: p<0.01; *: 0.01 
< p < 0.05 (red: differences from negative control cells; black: differences from pLL3.74-dsRed 
cells) as determined by 1-way ANOVA and post-hoc Scheffe test.  DIV 4, 8, and 12 n: Negative 
control cells (n=8, 12, 11), pLL3.74-dsRed cells (n=9, 9, 8), SCN1a WT (n=6, 9, 8), SCN1a 
A1685V (n=10, 9, 9), SCN1a L986F (n=9, 10, 7). 
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Parvalbumin (PV) expression was also examined for individual genotypes across time 
(Figure 17) and across genotypes on a given day (Figure 18).  Significance was evaluated using a 
1-way ANOVA and post-hoc Scheffe test.  Parvalbumin was largely localized to the soma on 
neurons and did not appear to be expressed by glia (Figure 16).  pLL3.74-dsRed (Figure 17b), 
SCN1a WT cells (Figure 17c), and A1685V cells had fairly stable PV expression over time, 
although WT cells did display a significant decrease in expression from DIV 8 to 12 (35% ± 3 to 
20% ± 4, p value: 0.021).  Negative control cells had elevated PV expression on DIV 4 but by 
DIV 8, their PV expression had come down to dsRed and WT levels (Figure 17a).  L986F 
mutants, on the other hand, displayed the lowest DIV 4 PV levels (16% ± 5), significantly higher 
expression levels on DIV 8 (58%, p value: 0.001), and a noticeable decrease on DIV 12 (26%; 
Figure 17e).  L986F’s increased PV expression on DIV 8 may indicate the network’s attempt to 
adapt to a reduced inhibition resulting from the SCN1a mutation.  The sudden decrease on DIV 
12 could potentially be a result of a loss of genotype due to nucleofection’s transient nature as 
nucleofection is only stable for 12-14 days. 
PV expression across genotypes on a given day was also variable (Figure 18).  On DIV 4, 
negative control and A1685V cells displayed the highest PV expression (Figure 18a).  WT cells 
had comparatively lower expression levels, but both dsRed and L986F cells had significantly 
lower PV expression than negative controls. (22% ± 3 and 16% ± 3 vs. 44% ± 8, respectively; p-
values of 0.049 and 0.008 respectively).  By DIV 8, a trend indicated that an average of 38% of 
negative control, dsRed, and SCN1a WT cells were expressing PV (Figure 18).  However, 
mutant cells were expressing comparatively higher levels of PV, possibly indicative of a subtle 
compensatory mechanism.  By DIV 12, however, the mutant’s increased PV expression was 
gone (Figure 18), possibly as a result of loss-of-genotype and a return to baseline PV expression. 
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Figure 16: Representative Images of Parvalbumin Expression 
 
 
 
Above: Representative images of parvalbumin expression.  A) Negative control cells (DIV 12), 
b) pLL3.74-dsRed cells (DIV 12), c) SCN1a WT cells (DIV 12), d) SCN1a A1685V cells (DIV 
8), e) SCN1a L986F cells (DIV 12).  DAPI: nuclei (blue), Alexa 647: parvalbumin (red). 
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Figure 17: Parvalbumin Expression over Time for Individual Genotypes 
 
 
 
Above: Average PV expression for individual genotypes on DIV 4, 8, and 12 ± standard error. *: 
0.01 < p < 0.05 as determined by 1-way ANOVA and post-hoc Scheffe test.  a) Negative control 
cells (n=6, 7, 6), b) pLL3.74-dsRed cells (n=6, 6, 6), c) SCN1a WT (n=6, 7, 6), d) SCN1a 
A1685V (n=6, 7, 7), e) SCN1a L986F (n=6, 6, 5). 
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Figure 18: Parvalbumin Expression Across Genotypes at a Given Age 
 
 
 
Above: Average PV expression across genotypes on individual days ± standard error. * 
represents a significant difference from negative control cells (p < 0.05) as determined by 1-way 
ANOVA and post-hoc Scheffe test.  DIV 4, 8, and 12 n: Negative control cells (n=6, 7, 6), 
pLL3.74-dsRed cells (n=6, 6, 6), SCN1a WT (n=6, 7, 6), SCN1a A1685V (n=6, 7, 7), SCN1a 
L986F (n=6, 6, 5). 
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Vesicular transporter 1 (Vglut1) expression was also fairly stable over time (Figure 20) 
and uniform across genotypes (Figure 21), making a down-regulation of Vglut1+ excitatory cells 
unlikely.  Vglut1 was present in the soma of neurons and glia and appeared more punctate in the 
axons over time (Figure 19).  SCN1a WT cells had uniform Vglut1 expression across all days 
(Figure 20c).  A small increase in Vglut1 expression from DIV 4 to 8 followed by a small 
decrease in expression from DIV 8 to 12 was observed in negative control cells (Figure 20a), 
A1685V cells (Figure 20d), and L986F cells (Figure 20e).  pLL3.74-dsRed cells displayed a 
similar trend, but the decrease from DIV 8 to 12 was significant in this case according to a 1-way 
ANOVA and post-hoc Scheffe test (76% ± 5 to 45% ± 6, p value of 0.021).  The slight increase 
in Vglut1 expression from DIV 4-8 may be due to gradual synapse maturity, as synapses begin to 
mature around DIV 7.  The slight decrease from DIV 8 to 12 is likely due to decreased viability 
as the culture aged.  Examining Vglut1 expression across genotypes on individual days reiterated 
fairly even Vglut1 expression on DIV 4 (Figure 21a), 8 (Figure 21b), and 12 (Figure 21c).  
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Figure 19: Representative Images of Vglut1 Expression 
 
 
 
Above: Representative images of Vglut1 expression in a) negative control cells (DIV 12), b) 
pLL3.74-dsRed cells (DIV 8), c) SCN1a WT cells (DIV 8), d) SCN1a A1685V cells (DIV 8), 
and e) SCN1a L986F cells (DIV 4).  DAPI: nuclei (blue), Alexa 647: Vglut1 (red).  Arrows 
indicate neuronal expression. 
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Figure 20: Vglut1 Expression Over Time for Individual Genotypes 
 
 
 
Above: Average Vglut1 expression for individual genotypes on DIV 4, 8, and 12 ± standard 
error. *: 0.01 < p < 0.05 as determined by 1-way ANOVA and post-hoc Scheffe test.  a) 
Negative control cells (n=6, 6, 8), b) pLL3.74-dsRed cells (n=7, 7, 6), c) SCN1a WT (n=6, 6 7), 
d) SCN1a A1685V (n=6, 6, 6), e) SCN1a L986F (n=6, 7, 6). 
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Figure 21: Vglut1 Expression Across Genotypes at a Given Age 
 
 
 
Above: Average Vglut1 expression across genotypes on individual days ± standard error.   DIV 
4, 8, and 12 n: Negative control cells (n=6, 6, 8), pLL3.74-dsRed cells (n=7, 7, 6), SCN1a WT 
(n=6, 6 7), SCN1a A1685V (n=6, 6, 6), SCN1a L986F (n=6, 7, 6) 
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Cellular localization of Nav1.1 displayed a small shift in Nav1.1 expression in axons and 
dendrites (Figure 24).  Nav1.1 was often expressed in the soma and axon while MAP2 was 
expressed in the soma and dendrites (Figure 22).  Although Nav1.1 and Tau1 are expressed in the 
axon, Nav1.1 was generally isolated to the axon initial segment, as expected (Figure 23).  
Nav1.1-MAP2 co-localization in most genotypes averaged around 57% However, Nav1.1 
dendritic expression in A1685V cells was noticeably lower at 45%.  Similarly, Nav1.1-Tau1 co-
localization averaged 53% for negative control, pLL3.74-dsRed, and L986F cells but was 
comparatively lower in A1685V cells (40% ± 5).  The combined reduction in axonal and 
dendritic expression contrasts A1685V’s overall Nav1.1 expression from DIV 8 which is similar 
to all other genotypes (Figure 15b).  This may indicate that A1685V cells have a similar number 
of cells expressing Nav1.1 but that the amount of Nav1.1 being expressed in processes is reduced.  
Additionally, Nav1.1 expression in axons was comparatively higher in SCN1aWT cells 
compared to negative control, pLL3.74-dsRed, and L986F cells (74% ± 6).  This may indicate 
that transfection with SCN1a WT causes an overexpression of Nav1.1 that is predominately 
affecting inhibitory neurons.  The combined increase in Nav1.1-Tau1 co-localization in 
SCN1aWT cells and decrease in A1685V cells leads to a significant difference between the two 
(p value: 0.026). 
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Figure 22: Representative Images of Nav1.1-MAP2 Co-localization 
 
 
 
Above: Representative images of Nav1.1 and MAP2 expression for negative control (a), 
pLL3.74-dsRed (b), SCN1a WT (c), SCN1a A1685V (d), and SCN1a L986F (e) cells.  Blue: 
nuclei (DAPI), green: Nav1.1 (Alexa 488), red: MAP2 (Alexa 647).  **Arrows indicate Nav1.1-
MAP2 co-localization in the soma and dendrites (b).  Arrows indicate Nav1.1-MAP2 co-
localization in the soma with MAP2 localization to the dendrites and Nav1.1 localization to the 
axon in a, c, d, and e.  Scale is the same for a, b, c, and e. 
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Figure 23: Representative Images of Nav1.1-Tau1 Co-localization 
 
 
 
Above: Representative images of Nav1.1 and Tau 1 expression for negative control (a), pLL3.74-
dsRed (b), SCN1a WT (c), SCN1a A1685V (d), and SCN1a L986F (e) cells.  Blue: nuclei 
(DAPI), green: Nav1.1 (Alexa 488), red: Tau1 (Alexa 647).  Glial expression of Nav1.1 indicated 
by * in a.  Arrows indicate Nav1.1-Tau1 co-localization to the soma only (a, e) or soma and axon 
initial segment (b, c, d).  Scale for a, b, and e are the same.  Scale for c and d are the same. 
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Figure 24: Nav1.1 Co-localization with MAP2 and Tau1 
 
 
 
Above: Average Nav1.1 co-localization with MAP2 (blue) and Tau1 (red) for various genotypes 
on DIV7 ± standard error.  *: p<0.05 as determined by 1-way ANOVA and post-hoc Scheffe 
test.  Negative control (n=6), pLL3.74-dsRed cells (n=6), SCN1a WT (n=6 for MAP2, 5 for 
Tau1), SCN1a A1685V (n=6), SCN1a L986F (n=5 for MAP2, 7 for Tau1). 
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In the case of Nav1.1 and PV, co-localization was fairly constant across days and 
genotypes (Figure 26 & Figure 27).  Nav1.1 was expressed in the soma of both neurons and glia, 
but was also present in the axon initial segment of PV+ cells, while PV was mainly expressed in 
neuronal somas (Figure 25).  Looking at individual genotypes over time, SCN1a WT cells 
displayed a small decrease between DIV 4 and 8 but, in general, expression remained consistent 
(Figure 26c).  Negative control cells displayed a gradual increase in co-localization from DIV 4 
to DIV 12 (32% ± 3 to 58% ± 6, p value: 0.016; Figure 26a).  The remaining pLL3.74-dsRed, 
A1685V, and L986F cells all showed trends where Nav1.1-PV co-localization increased from 
DIV 4 to 8 then decreased from DIV 8 to 12 (Figure 26 b, d, e).  However, this trend was only 
significant between DIV 4 and 8 for A1685V cells (p value: 0.027). 
Examination across genotypes on individual days also showed some variability in trends 
(Figure 27).  On DIV 4, negative control, pLL3.74-dsRed, and L986F cells had Nav1.1-PV co-
localization values of around 36% (Figure 27a).  However, SCN1a WT cells had noticeably 
higher co-localization while A1685V cells had noticeably lower co-localization, leading to a 
significant difference between the two (p value: 0.008).  This disparity in co-localization 
between Nav1.1 and PV could indicate an overexpression of Nav1.1 in PV
+ neurons for WT cells 
and a reduced expression of Nav1.1 in PV
+ neurons in A1685V cells early on, possibly due to 
their respective genotypes.  By DIV 8, both WT and A1685V cells displayed Nav1.1-PV co-
localization near that of the other genotypes (Figure 27 b).  Neither DIV 8 nor 12 show any 
significant differences between genotypes (Figure 27 b and c).  The fact that WT and A1685V 
cell’s Nav1.1-PV co-localization caught up to that of the remaining genotypes may indicate a 
subtle compensatory down-regulation of Nav1.1 expression on PV
+ cells in WT networks and a 
subtle up-regulation in A1685V cells. 
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Figure 25: Representative Images of Nav1.1-Parvalbumin Co-expression 
 
 
 
Above: Representative images of Nav1.1-PV co-expression for a) negative control cells (DIV 8), 
b) pLL3.74-dsRed cells (DIV 8), c) SCN1a WT cells (DIV 8), d) SCN1a A1685V cells (DIV8), 
e) SCN1a L986F cells (DIV 4).  DAPI: nuclei (blue), Alexa 488: Nav1.1 (green), Alexa 647: PV 
(red).  Arrows indicate PV+ cells with Nav1.1 localized to the soma and axon initial segment. 
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Figure 26: Nav1.1-Parvalbumin Co-localization Over Time for Individual Genotypes 
 
 
 
Above: Average Nav1.1-PV co-localization for individual genotypes on DIV 4, 8, and 12 ± 
standard error. *: 0.01 < p<0.05 as determined by 1-way ANOVA and post-hoc Scheffe test.  a) 
Negative control cells (n=6, 6, 8), b) pLL3.74-dsRed cells (n=5, 6, 6), c) SCN1a WT (n=5, 5 5), 
d) SCN1a A1685V (n=5, 6, 6), e) SCN1a L986F (n=5, 5, 5). 
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Figure 27: Nav1.1-Parvalbumin Co-localization Across Genotypes at a Given Age 
 
 
 
Above: Average Nav1.1-PV co-localization for across genotypes on DIV 4, 8, and 12 ± standard 
error. **: p value < 0.01 as determined by 1-way ANOVA and post-hoc Scheffe test.  DIV 4, 8, 
and 12 n: Negative control cells (n=6, 6, 8), pLL3.74-dsRed cells (n=5, 6, 6), SCN1a WT (n=5, 5 
5), SCN1a A1685V (n=5, 6, 6), SCN1a L986F (n=5, 5, 5) 
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Similar co-localization uniformity was observed for Nav1.1 and Vglut1 across genotypes 
and age (Figure 29 & Figure 30).  Nav1.1 was mainly expressed in the soma of both glia and 
neurons, but was present in the beginnings of dendritic processes in Vglut1+ cells (Figure 28).  
Negative control cells displayed a significant increase in Nav1.1-Vglut1 co-localization from 
DIV 4 to 8 and 8 to 12 (38% ± 4 vs. 43% ± 4 and 38% ± 4 vs. 75% ± 8; p values: 0, and 0 
respectively; Figure 29a).  pLL3.74-dsRed (Figure 29b), A1685V (Figure 29d, and L986F; 
Figure 29e) cells all showed trends with slight increases in co-localization between DIV 4 and 8 
but similar or slightly reduced expression on DIV 12.  WT cells had fairly similar Nav1.1-Vglut1 
co-localization on all days (Figure 29c). 
No significant difference in Nav1.1-Vglut1 co-localization was observed across 
genotypes at a given age (Figure 30).  DIV 4 Nav1.1-Vglut1 co-localization was fairly consistent 
between 38 and 51% (Figure 30a).  On Nav1.1-Vglut1 co-localization generally increased from 
DIV 4 to DIV 8 (Figure 30b), possibly due to changes in Vglut1+ cells during synapse 
development.  By DIV 12, Nav1.1-Vglut1 co-localization was again uniform across genotypes 
(Figure 30c). 
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Figure 28: Representative Images of Nav1.1-VGlut1 Co-expression 
 
 
 
Above: Representative Images of Nav1.1-Vglut1 co-expression.  A) Negative control cells (DIV 
8); b) pLL3.74-dsRed cells (DIV 8), c) SCN1a WT cells (DIV 8), d) SCN1a A1685V cells (DIV 
8), e) SCN1a L986F cells (DIV 12).  Arrows indicate Nav1.1 expression in the soma and early 
dedritic processes.  * denotes glial co-localization.  DAPI: nuclei (blue), Alexa 488: Nav1.1 
(green), Alexa 647: Vglut1 (red). 
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Figure 29: Nav1.1-Vglut1 Co-localization in Individual Genotypes Across Time 
 
 
 
Above: Average Nav1.1-Vglut1 co-localization for individual genotypes on DIV 4, 8, and 12 ± 
standard error. **: p value < 0.01 as determined by 1-way ANOVA and post-hoc Scheffe test.  a) 
Negative control cells (n=5, 6, 6), b) pLL3.74-dsRed cells (n=6, 6, 6), c) SCN1a WT (n=5, 5 6), 
d) SCN1a A1685V (n=5, 5, 5), e) SCN1a L986F (n=6, 6, 5) 
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Figure 30: Nav1.1-Vglut1 Co-localization Across Genotypes at a Given Age 
 
 
 
Above: Average Nav1.1-Vglut1 co-localization for across genotypes on DIV 4, 8, and 12 ± 
standard error. **: p value < 0.01 as determined by 1-way ANOVA and post-hoc Scheffe test.  
DIV 4, 8, and 12 n: Negative control cells (n=5, 6, 6), b) pLL3.74-dsRed cells (n=6, 6, 6), c) 
SCN1a WT (n=5, 5 6), d) SCN1a A1685V (n=5, 5, 5), e) SCN1a L986F (n=6, 6, 5) 
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3.4 DISCUSSION 
The purpose of this chapter was to determine whether transfection with SCN1a plasmids 
impacts culture composition and Nav1.1 protein expression and localization.  Studies indicate 
that transfection did not appear to alter the phenotype of transfected vs. un-transfected controls 
indicating that any changes between controls and experimental genotypes were likely due to the 
exogenous DNA introduced.  Furthermore, the overall ratio of excitatory to inhibitory neurons 
was consistent with previous studies in in vitro neurons.  Typically, the majority of dissociated 
rodent hippocampal cultures are excitatory cells with at least 20% being inhibitory [134, 135].  
The fact that the average excitatory to inhibitory ratio remained stable across genotypes indicates 
that a stable compensatory up-regulation of inhibitory cells or down-regulation of excitatory cells 
did not take place for the cell markers we studied.  However, other compensatory mechanisms 
may be at play [100].  For instance, other subsets of inhibitory cells may be over-expressed in 
order to provide additional network inhibition.  In this case, we used the inhibitory marker 
parvalbumin because of its presumed role in epilepsy and previous association with Nav1.1.  
However, a more general anti-GABA marker might reveal more subtle changes in Nav1.1 
expression.  
Additionally, parvalbumin expression displayed subtle changes over time and may 
warrant closer inspection.  Compared to other genotypes, negative control cells had higher PV 
expression early on possibly indicating that the transfection process may impact the early 
development of PV cells (Figure 18a).  More interestingly, L986F cells displayed similar PV 
expression levels to transfection control cells early on (Figure 18a) but had noticeably higher PV 
expression at DIV 8 (Figure 18b) followed by a drop down to DIV 4 levels on DIV 12 (Figure 
18c).  This may indicate a compensatory increase in PV expression followed by a return to 
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baseline expression levels following loss of transfection, but as these trends were subtle, they 
require more investigation. 
Furthermore, Nav1.1 expression appeared consistent across genotypes.  It was somewhat 
surprising that SCN1a mutations did not affect overall Nav1.1 expression.  However, 
examination of Nav1.1 expression in axons and dendrites did indicate a possible phenotypic 
effect of SCN1a transfection.  Although dendritic expression of Nav1.1 was similar in controls, 
WT, and L986F cells, it was comparably lower in A1685V cells (Figure 24).  Similarly, axonal 
expression of Nav1.1 was comparable in controls and L986F cells but a decrease in axonal 
expression was noted for the mild mutant A1685V cells (Figure 24).  The combined decrease in 
Nav1.1 axonal and dendritic expression in A1685V cells compared to other genotypes is likely a 
result of the introduced Nav1.1 mutation.  However, the overall Nav1.1 expression for A1685V 
cells measured on DIV 8 was not noticeably lower than other genotypes (Figure 15c).  This may 
indicate that although the same number of cells are expressing Nav1.1 in A1685V cells around 
DIV 7-8, the amount of Nav1.1 being expressed in processes is lower. 
Additionally, SCN1a WT cells demonstrated increased axonal Nav1.1 expression 
compared to other genotypes (Figure 24).  This may indicate that transfection is leading to 
Nav1.1 over-expression in WT cultures and is mostly impacting inhibitory cells, possibly because 
they are believed to express Nav1.1 more readily than excitatory cells [107].  Furthermore, both 
negative control and SCN1a WT cells show a higher ratio of axonal vs. dendritic Nav1.1 
expression while pLL3.74-dsRed cells are split evenly.  This is not surprising because inhibitory 
cells are thought to express Nav1.1 more readily than excitatory cells (explaining the slight 
increase in axonal expression) but the greater ratio of excitatory to inhibitory cells may keep 
axonal and dendritic expression fairly even, especially when glia are factored in.  Glia are known 
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to express Nav1.1 and reactive glia have been shown to express MAP2, which may skew 
dendritic expression upward.  However, both A1685V and L986F cells show slightly higher 
levels of dendritic expression instead, possibly indicating that the introduced SCN1a mutation is 
affecting Nav1.1 expression in inhibitory cells in our SCN1a mutants. 
Finally, protein expression decreased in a number of instances between DIV 8 and 12.  
This may be due to cell death, a loss of transfection stability or a combination of the two.  
Similar preparations of in vitro hippocampal neurons can generally be maintained for 2 to 3 
weeks, but cell death often begins around DIV 12.  Additionally, nucleofection is only stable for 
12-14 days.  Therefore, changes in Nav1.1 expression on DIV 12 in WT, A1685V, or L986F 
cells could be due to a loss of genotype.  Additionally, these two constraints may limit future 
studies involving long-term synapse development as synapses begin maturing around DIV 7 and 
continue to mature through DIV 21.  Therefore, this model is currently limited to examining 
protein expression and early synapse development, but could provide information regarding early 
disease development. 
3.5 CONCLUSIONS 
In summary, this chapter illustrates our ability to examine changes in culture composition 
following transfection of SCN1a plasmids.  While no significant compensatory mechanism was 
observed, several subtle trends do warrant closer inspection.  These include density of Nav1.1 
expression in processes of mild mutants, early PV expression in negative control cells, and 
Nav1.1 co-localization with other inhibitory cell markers. 
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4.0  FUNCTIONAL ANALYSIS OF DEFINED NETWORKS 
4.1 INTRODUCTION 
Phenotypic analysis of protein localization is not sufficient to assess the effect of SCN1a 
mutations on neural networks.  Because epilepsy is a disease based in aberrant electrical activity, 
examining the functional consequences of SCN1a mutations on network activity is critical.  This 
chapter is focused on using calcium imaging to examine if and how SCN1a mutations impact 
activity in constrained neural networks in the presence of seizure agonists and antagonists. 
4.1.1 Calcium Imaging, Epilepsy, and Constrained Neuronal Networks 
Calcium is one of many intracellular messengers in the brain.  At rest, calcium levels inside the 
cell are low, but this can rapidly increase during neuronal activity as voltage-gated calcium 
channels and N-methyl-D-aspartate (NMDA) receptors open to allow calcium to enter the cell.  
Intracellular calcium signals vary by time course and amplitude, so studying calcium transients 
can provide insight into cellular activity in both healthy and diseased networks [136].  To that 
end, calcium imaging has been applied to a number of research areas including the development 
of epilepsy, or epileptogenesis, in the cortex and hippocampus [137, 138]. 
In 2001, Yuste et al. used the calcium-sensitive dye Fura-2 to examine individual 
neurons’ activity in bicuculline-induced epilepsy-like, or epileptiform events, in mouse 
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somatosensory cortex slices [138].  Yuste’s group applied bicuculline methiodide (BMI) to tissue 
and observed epileptiform activity after 30 minutes.  Bicuculline is a competitive GABAA 
receptor antagonist that effectively blocks inhibition in a network, creating the hyperexcitability 
characteristic of epilepsy.  Yuste’s work resulted in both fast and slow calcium transients.  The 
majority of calcium transients were classified as fast, correlated with epileptiform events, and 
were not present when TTX was used to block sodium channel activity.  Slow calcium transients, 
on the other hand, appeared spontaneously and persisted in spite of TTX application. 
In 2010, Zeringue et al. performed a parallel study using the calcium-sensitive dye Fluo4-
AM with in vitro cultures of E18-E19 rat hippocampal neurons [92].  In this case, microcontact 
printing was used to constrain network geometry, creating small networks of 40-60 neurons 
adhered to poly-L-lysine “rings” on glass coverslips.  Following electrical stimulation, the 
networks displayed a brief increase in electrical activity as expected, typically lasting 60 ms with 
a 2-4 s decay.  However, a subset of control cultures displayed “reverberation,” defined as 
network activity persisting >2 s after the cessation of the input stimulus.  This persistent activity 
involved a 6 fold increase in fluorescence over the first 2 seconds followed by a gradual signal 
decay.  The Zeringue group found that after 10 M bicuculline treatment, reverberation was 
observed in 100% of cultures.  However, reverberation was both brighter and longer lasting 
when BMI was present compared to the control HBS bath.  When the calcium chelator EGTA-
AM was added, persistent activity was effectively blocked.  Zeringue et al’s work raised the 
question, “if prolonged ‘seizure-like’ activity can be triggered chemically in constrained 
networks, can it also be triggered genetically?”  Therefore, the working hypothesis for this 
chapter was that mutations in the voltage-gated sodium channel Nav1.1 likely impact network 
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functionality.  If this hypothesis were correct, then expression of mutant SCN1a subunits should 
modify the functional activity of constrained networks. 
4.1.2 GEFS+ and AEDs 
Generalized Epilepsy with Febrile Seizures Plus, Type II (GEFS+) is a spectrum epilepsy 
disorder that ranges from mild, generally controllable seizures with normal development to the 
more extreme Severe Myoclonic Epilepsy of Infancy (SMEI) which typically presents with 
intractable seizures and severe developmental delays.  Although the majority of GEFS+ 
epilepsies are originally associated with fever-related seizures, over time, patients can exhibit 
non-febrile, generalized, or partial seizures which are often drug resistant and can sometimes 
even be exacerbated by anti-epileptic drugs (AEDs) [139].   Liao et al. studied the effect of 
AEDs on GEFS+ and SMEI using TSa201 cells [104].  Both GEFS+ and SMEI involve a loss of 
sodium channel function due to SCN1a missense mutations.  However, GEFS+ is less severe, 
possibly because its missense mutations, including A1685V, do not involve a change in residue 
hydrophobicity.  While some AEDs had no effect, sodium channel blocking AEDs like 
lamotrigine (LTG), phenyoin (PHT), and carbamazepine (CBZ) did trigger seizure activity.  If 
SCN1a related seizures are caused by a lack of inhibition, using sodium channel blocking AEDs 
could intensify the problem by further decreasing the inhibitory activity of available interneuron 
sodium channels without adequately lowering activity in excitatory cells.  Although AED 
aggravated seizure activity may be linked to dosage, several groups have suggested new AEDs 
that do not target sodium channels should be explored in an effort to help epilepsy patients with 
diseases like GEFS+ and SMEI [140] [104]. 
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Although some AEDs like CBZ and LTG exacerbate seizures in some GEFS+ patients, 
others, like valproic acid (VPA), have shown some success in controlling GEFS+.  For instance, 
in 2010, Escayg et al demonstrated that 100-300 mg/kg of VPA administered to SCN1a knock-
out mice increased the time between seizure episodes and that the effect was magnified increased 
with increasing dose.  Additionally, VPA helped return heterogeneous knock-out mice’s elevated 
febrile seizure threshold to normal [141]. 
We focused our study on one AED known to aggravate seizure activity in GEFS+ patients 
(referred to as AED-) and one that is known to alleviate them (referred to as AED+).  In this case, 
our AED- is carbamazepine (CBZ) and our AED+ is valproic acid (VPA).  CBZ preferentially 
binds to voltage-gated sodium channels in the inactive state, causing the channel to become 
inactive at less negative membrane potentials (essentially making it inactive sooner).  CBZ also 
prolongs the refractory period by delaying the channel’s return from inactive to closed, resting 
state following hyperpolarization [57].  Although CBZ is commonly used for treating some types 
of epilepsy, it is not generally prescribed for GEFS+ as it tends to trigger, rather than prevent, 
seizures.  This is likely because CBZ impacts both excitatory and inhibitory cells, so even though 
excitatory cell activity is reduced, it is not enough to overcome the further reduction of inhibitory 
cell activity in a network already displaying decreased inhibition, leading to intensified seizure 
activity.  On the other hand, valproic acid (VPA) is an anti-epileptic drug commonly prescribed 
to GEFS+ patients.  VPA serves as an AED in two ways.  First, it blocks voltage-gated sodium 
channels to reduce network excitability [142].  Secondly, it is believed to inhibit release of 
gamma hydroxybutyrate, a chemical that binds to excitatory receptors, leading to an overall 
decrease in excitation [143].  Both mechanisms increase the activity of functional inhibitory cells 
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in a network and help compensate for inhibitory neurons which have been compromised by 
GEFSmutations. 
In short, GEFS+ is a neurological disease characterized by abnormal network 
functionality, but it is rarely studied in vitro in neurons.  Calcium imaging is often used to study 
network functionality in in vitro neurons and previous studies indicate that it can be used to study 
seizure-like behavior in constrained networks.  Therefore, we propose to pair calcium imaging 
with constrained neural networks expressing GEFS+-related genetic mutations to assess network 
functionality. 
4.2 MATERIALS & METHODS 
4.2.1 Master Fabrication 
In this project a polydimethylsiloxane (PDMS) stamp was used to pattern surfaces and constrain 
network geometry.  A silicon master, from which the stamp was cast, was first created.  To do 
so, a 3” silicon wafer (University Wafer) was cleaned with acetone, IPA, and DDW to remove 
organic residue then dried with a nitrogen gun.  After baking for 5 minutes at 200oC to remove 
solvent residue, ~50 m of SU-8 3035 (Microchem, Westborough, MA) was applied using a 
two-step spin process (10 seconds at 500 rpm with a 100 rpm/s ramp up, 30 seconds at 2000 rpm 
with a 300 rpm/s ramp up).  The wafer was then soft baked for 8 minutes, 32 seconds at 95oC 
and briefly cooled until a thin film formed to prevent the photomask from sticking to the wafer 
surface.  Next, a photomask was placed on the wafer, covered with a thin piece of Pyrex glass to 
ensure good contact between the wafer and mask, and exposed to UV for 12 seconds.  The 
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master was post-exposure baked for 1 minute at 65oC then 4 minutes at 95oC before being 
developed by immersing the wafer in SU-8 developer (Microchem, Westborough, MA) for 8 
minutes.  Following development, the wafer was rinsed with IPA & DDW and gently dried with 
a nitrogen gun. To improve adhesion and anneal any surface cracks, the master was hard baked 
for 2 minutes at 150oC.  After cooling to room temperature, the master was visually inspected for 
defects using a stereoscope.  The final stamp pattern consisted of a 6x10 grid of annuli, each with 
an outer diameter of 300 m and an inner diameter of 100 m. 
4.2.2 Stamp Fabrication 
Once a silicon master was fabricated, a PDMS stamp could be created from it.  In this case, 
PDMS (Dow Corning, Midland, MI) was combined in a 10:1 pre-polymer:curing agent ratio.  
Briefly, the pre-polymer was weighed out in a plastic cup and an appropriate amount of curing 
agent was added.  The solution was then thoroughly mixed and placed in a desiccator to remove 
any air bubbles that formed during the mixing process.  A master containing the desired pattern 
was rinsed with methanol and DDW and dried with a nitrogen gun before PDMS was slowly 
poured over it.  The PDMS coated master was then baked for two hours at 80oC.  Once the wafer 
cooled to room temperature, the stamping section was removed with a scalpel and spatula before 
being visually inspected with a stereoscope.  Stamps were stored in DDW until needed. 
4.2.3 Coverslip Preparation 
Prior to experimental use, all glass coverslips were cleaned in an effort to promote neuronal 
adhesion and growth.  Briefly, coverslips were submerged in sterile distilled, deionized water 
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(DDW) for 15 minutes on a shaker before being transferred to 70% nitric acid and left on a 
shaker for 24-48 hours.  Coverslips were then rinsed in sterile DDW (3 times at 5 minutes each 
followed by 3 times at 20 minutes each) and stored in 70% ethanol until needed.  Immediately 
before harvesting tissue, cleaned coverslips were briefly flamed, stamped with PLL as outlined 
in 4.2.2, and placed in plating medium before being stored in a 5% CO2, 37
oC incubator to 
equilibrate. 
4.2.4 Stamping Protocol 
A level stamp face is necessary for proper stamping.  Therefore, once a stamp was complete, its 
evenness was evaluated using FITC-tagged PLL.  Stamps were cleaned with IPA and DDW then 
dried with a nitrogen gun to remove any surface debris.  Just prior to stamping, the stamp was 
exposed to an oxygen plasma for one minute.  Plasma exposure made the stamp more 
hydrophilic and promoted even protein adsorption across the stamping surface.  Next, a small 
amount of FITC-tagged PLL (2 g/L in PBS) was added to the stamp’s surface.  The protein 
was allowed to dry for several seconds.  Once it appeared dry, the stamp was gently placed face 
down on a substrate using tweezers.  Care was taken to keep the stamp from shifting once in 
contact with the substrate.  To ensure even pressure was applied across the entire stamping 
surface, a series of glass plates were added (two 20 g plates and one 40 g plate).  The stamp was 
allowed to dry for one minute before being removed from the substrate using tweezers.  Again, 
care was taken to keep the stamp from dragging along the surface of the substrate.  After at least 
5 minutes had passed, the stamped coverslip was briefly rinsed with culture water to remove 
excess protein build-up.  Patterned substrates were then visually inspected using a fluorescent 
microscope.  Once a stamp was deemed adequate, the stamping procedure was repeated on clean 
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coverslips with 1 mg/mL PLL in borate buffer directly before a harvest began.  Stamped 
coverslips were stored in a 5% CO2, 37
oC incubator between stamping and plating. 
4.2.5 Neuronal Harvest, Nucleofection, and Culture 
Briefly, E18-E19 rat hippocampal neurons were isolated from freshly harvested tissue in 
accordance with the University of Pittsburgh’s IACUC guidelines.  Immediately after isolation, 
cells were nucleofected with 1-3 g of either pLL3.74-dsRed alone or co-nucleofected with 
pLL3.74-dsRed and one of three SCN1a plasmids (wild type, A1685V, or L986F) using a Rat 
Neuron Nucleofector Kit (Lonza, Walkersville, MD).  Cells were cultured in media comprised of 
96% Neurobasal, 2% B27 (50x), 1% pen-strep, 0.25% 200 mM glutamate, and 0.125% 10 mM 
glutamate in 10 mM HCl for up to 14 days. 
4.2.6 Time-Lapse Calcium Imaging 
DIV 10-13 E18-E19 rat hippocampal neurons were incubated with 2.5 mL of Fura2-AM and 2.5 
mL of Pluronic 125 in 2.5 mL warm HBS solution for 20 minutes in the dark.  Cells were then 
placed in a clean dish of warm HBS for 20 minutes in the dark.  Once cells were ready, warm 
HBS was added to the perfusion system and the vacuum was adjusted until flow was steady and 
uniform.  After selecting the desired field of view, a bipolar field electrode was placed near a cell 
on the ring.  Cells were selected using the ROI selection tool in MetaFlour software (Molecular 
Devices, Sunnyvale, CA) and a baseline bright field image was taken.  Fluorescence of selected 
ROIs were then verified and any pLL3.74-daRed+ cells were identified.  60 seconds of baseline 
340/380 fluorescence was obtained before any stimulation began.  Three minutes of stimulus 
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response data was then obtained, with a 30 V stimulus being applied for 5 seconds (2 s pulses 
with 200 ms intervals beginning 4 seconds into a trial).  Following three trials for a given bath, 
the subsequent bath was perfused onto the cells for two minutes before a new stimulus trial 
began.  In between coverslips, 50 mL of DDW was perfused through the system to remove any 
residual bath solution. 
Prior to drug trials, baseline trials were performed to ensure that recovery times between 
stimulation would be sufficient.  In this case, cells were exposed only to a control HBS bath.  
Stimulation was repeated 5 times using experimental stimulation parameters.  Traces were 
visually assessed for dampening and repeatability. 
For drug trials, final bath solutions were: HBS, 10 M BMI, 0.6 mM VPA, 10 M CBZ, 
and 30 mM high K+ HBS.  Trials were as follows: VPA with BMI (i.e. HBS, BMI, VPA, high 
K+ baths applied in sequential order), VPA without BMI (i.e. HBS, VPA, and high K+ baths 
applied in sequential order), CBZ with BMI (i.e. HBS, BMI, CBZ, and high K+ baths applied in 
sequential order), CBZ without BMI (i.e. HBS, CBZ, and high K+ baths applied in sequential 
order).  Each drug trial was repeated in three different cultures.  Resulting 340/380 fluorescence 
vs. time profiles were analyzed in Excel and SPSS v.22 (IBM, Chicago, IL).  Data was reported 
as resulting p-value, effect size, and general trend. 
4.2.7 Statistical Analysis 
Statistical analysis was performed using SPSS v. 22 (IBM, Chicago, IL).  Because data was not 
normally distributed, a non-parametric Kruskal-Wallis test was used to assess significance while 
2 was used to determine effect size [112].  Effect size of 0.2-0.12 was considered small, 0.13-
0.25 was considered medium, and 0.26 or higher was considered large.  Before beginning 
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statistical analysis, unresponsive cells were discarded.  We defined unresponsive cells as those 
whose starting Fmax (the maximum 340/380 value recorded during the one minute of baseline 
activity proceeding each stimulation) was less than 0.05 units from its Fmax following 
stimulation.  Once the final data set was ready, we accounted for variable baselines by 
normalizing data to a trial’s average baseline value then logarithmically transforming the data 
set. 
4.2.8 In Vitro Toxicology Testing 
Because AED studies are not often done in neurons in vitro, we elected to determine drug dosing 
prior to calcium imaging using a Trypan blue exclusion assay [144]. To assess cytotoxicity of 
given bath solutions, a Trypan blue exclusion assay was used on DIV 10 E18-E19 rat 
hippocampal neurons.  To begin, cells were perfused with warm HBS for 3-5 minutes at room 
temperature before being exposed to a drug bath for 15 minutes.  Immediately following drug 
exposure, cells were rinsed with warm HBS for 1 hour with solution changes every 10 minutes to 
remove any drug traces.  After 1 hour, cells were briefly placed in a 0.4% Trypan blue solution 
(<1 min.) and rinsed in room temperature HBS to remove excess dye.  Cells were then placed in 
cold 4% PFA for 30 minutes at 4oC.  Afterward, cells were rinsed with PBS and dehydrated in an 
ethanol series (twice for 30 minutes each in DDW, 3 minutes in 50% ethanol, 3 minutes in 80% 
ethanol, twice for 3 minutes each in 95% ethanol, and 3 minutes in 100% ethanol).  Cells were 
then mounted with Fluoromount G before being imaged at 20x.  The number of Trypan blue 
positive cells vs. the total number cells in three random ROIs was used to calculate cytotoxicity 
(cell toxicity was defined as the percent of Trypan blue positive cells in a given ROI).  Data is 
presented as the mean ± standard error of the mean.  A one-way ANOVA was performed to 
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determine statistically significant differences between groups.  Post-hoc analysis was performed 
using a Scheffe test (SPSS v22, Chicago, IL). 
In these studies, we selected three doses to test per drug.  These were presumed to be sub-
therapeutic, therapeutic, and toxic based on literature review.  For CBZ, those doses were 1 M 
(sub therapeutic), 10 M (therapeutic), and 100 M (toxic).  For VPA doses wereM (sub 
therapeutic), 0.6 mM (therapeutic), and 5 mM (toxic).  These ranges were selected for evaluation 
based on available literature as well as calculations involving common doses and estimated 
blood brain barrier permeability for each drug.  BMI was not subject to toxicity testing as it is 
commonly used in in vitro culture work.  These studies used 10 M BMI because previous 
studies showed little results with BMI below 10 M [92]. 
4.3 RESULTS 
In this chapter, ring shaped networks of transfected and un-transfected neurons were successfully 
generated (Figure 31b).  Even distribution of the cell adhesion protein poly-L-lysine encouraged 
cell adhesion across the ring and prevented neurospheres from forming (Figure 31a).  The 
average number of cells per ring network was found to be slightly lower at ~30 cells/ring than 
the previously reported 40-60 cells/ring in un-transfected ring networks [92].  Overall, our ring 
networks averaged 31 cells/ring (33 ± 1.66 for negative control networks, 33 ± 2 for pLL3.74-
dsRed networks, 30 ± 2 for SCN1aWT networks, 33 ± 2 for SCN1a A1685V networks, and 27 ± 
2 for SCN1a L986F networks; Figure 32).  The number of cells per ring was uniform across most 
genotypes with the only exception being a significantly higher number of A1685V cells 
compared to L986F cells.   
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Figure 31: Microcontact Printing Ring Patterns 
 
 
 
Above: a) Glass coverslip stamped with FITC-tagged PLL (2 mg/mL in PBS).  b) Neurons 
growing on stamped substrate.  Blue: nuclei (DAPI); red: MAP2 (Alexa 647). 
 
 95 
 
 
 
Figure 32: Average Number of Cells per Ring Network 
 
 
 
Above: Average number of cells per ring for various genotypes ± standard error.  *: p<0.05 as 
determined by 1-way ANOVA and post-hoc Scheffe test 
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Prior to calcium imaging experiments, we assessed drug toxicity using a Trypan blue 
exclusion assay.  VPA and CBZ appeared to have a dose-dependent effect on cell death across 
all genotypes (Figure 33).  Similar levels of cell death occurred in control baths for both drug 
trials, which is to be expected as the same control bath composition was used in both tests.  
Valproic acid induced cell death was determined to be 11% ± 1 for HBS control bath, 14% ± 1 
for 0.06 mM (sub therapeutic dose), 19% ± 1 for 0.6 mM (therapeutic dose), and 24% ± 1 for 0.6 
mM (toxic dose) (Figure 33a).  Carbamazepine induced cell death was determined to be 10% ± 1 
for HBS control bath, 13% ± 1 for 1 M (sub therapeutic dose), 17% ± 1 for 10 M (therapeutic 
dose), and 22% ± 1 for 100 M (toxic dose) (Figure 33b).  In general, cell death increased with 
increasing drug dose in both cases, with all genotypes displaying a significantly higher cell death 
in the toxic dose compared to the control HBS bath.  Cell death was approximately the same for 
the control HBS bath and the low doses of each drug, although the low dose of VPA resulted in a 
significantly higher cell death in L986F cells while the low dose of CBZ resulted in a 
significantly higher cell death in SCN1aWT cells. 
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Figure 33: Valproic Acid & Carbamazepine Induced Cell Death 
 
 
 
Above:  Anti-epileptic drug induced cell death from valproic acid (a) and carbamazepine (b). 
Data are presented as the mean ± standard error of the mean. *: p<0.05; **: p<0.01 between a 
given drug dose and the control HBS bath, as determined by 1-way ANOVA and post-hoc 
Scheffe test. 
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Before beginning calcium imaging drug trials, baseline images were collected to evaluate 
rest times between stimulation.  Repeatable traces were obtained for all five stimulations in 
negative control and pLL3.74-dsRed trials (Figure 34a and b).  Wild type networks experienced 
some dampening, typically beginning at the fourth stimulus (Figure 34c).  Both A1685V and 
L986F cultures displayed more prolonged responses (responses to stimuli that do not recover to 
pre-stimulus levels) as stimulation progressed (Figure 34d and e).  Additionally, they were prone 
to some signal dampening beginning around the fourth consecutive stimulation (data not shown). 
Figure 34 also provides examples of the variety of responses commonly seen during our 
calcium imaging experiments including: spontaneous activity (panels a, d, and e); prolonged 
response to stimuli (panels a, b, c, d, and e); and oscillatory behavior (panels c and d).  While 
most genotypes displayed spontaneous and prolonged activity at some point during a trial, 
transfected cells appeared to be more likely to display prolonged responses and oscillatory 
behavior. 
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Figure 34: Representative Traces of Baseline Calcium Activity 
 
 
 
Above: representative calcium imaging traces of 340/380 vs. time recorded during 
baseline trials for a) negative control cells, b) pLL3.74-dsRed cells, c) SCN1a WT cells, d) 
SCN1a A1685V cells, e) SCN1a L986F cells.  Arrows: oscillatory behavior; *: prolonged 
activity; +: spontaneous activity.  Stimulations are indicated by vertical lines. 
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Following preliminary calcium imaging studies, we began initial drug trials.  In induced 
trials, bicuculline methiodide (BMI) was used to induce seizure activity prior to AED 
application.  High K+ was added at the end of each experiment to ensure that networks were still 
active.  Additionally, drug trials were performed without BMI application to investigate intrinsic 
changes in network activity.  In all cases, calcium responses were fairly variable between trials 
for the same genotype and same drug, making data analysis challenging.  In the end, we decided 
to focus on three of our five original genotypes (negative control cells, pLL3.74-dsRed, and 
A1685V cells). 
For all experiments, cell activity was assessed by calculating the time needed to reach 
maximum fluorescence, or Time-to-Fmax, following electrical stimulation.  We assumed an 
increase in Time-to-Fmax (TTF) to indicate an increase in activity because a higher Fmax should 
take longer to reach or because cells that have prolonged responses to stimuli may have a 
delayed Fmax (Figure 35). 
 
 
 
 
 101 
 
 
 
 
 
Figure 35: Connection Between Time-to-Fmax and Cell Activity 
 
 
 
Above: Schematic of Time-to-Fmax (TTF) for a cell with a moderate response (blue), an 
elevated response (green), and a prolonged response (pink) demonstrating how elevated or 
prolonged responses are likely to result in a longer TTF. 
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In BMI + VPA trials, an increase in TTF from HBS to BMI baths was observed in both 
pLL3.74-dsRed and A1685V, as expected (Table 6).  Although this trend was not significant, it 
did have a small effect size.  Negative control cells, on the other hand demonstrated a decrease in 
TTF.  This unexpected result paired with the lack of significance and low effect size may 
indicate that BMI dose was too low.  However, a significant decrease in activity was noted for all 
genotypes when comparing HBS to VPA and BMI to VPA, also as expected.  When looking at 
HBS to high K+ results, a medium increase was seen for all genotypes, but this was only 
significant in transfected and un-transfected controls, possibly indicating that A1685V cells are 
not recovering as quickly from VPA-reduced activity as the controls.  Finally, increases in TTF 
were observed when comparing BMI to high K+ and VPA to high K+ for all genotypes, as 
expected.  However, this trend is only significant for pLL3.74-dsRed cells.  The lack of 
significance when comparing BMI to high K+ may be because cells reach a maximum increase in 
activity when exposed to BMI and are therefore not able to exceed that during high K+ exposure.  
The lack of significance when comparing VPA to high K+ may indicate that, although cells 
respond to high K+, their activity is too depressed from VPA exposure to significantly recover in 
the time allotted.  Representative traces illustrate the subtle trends observed as well as the 
variability within single trials (Figure 37). 
In intrinsic VPA trials, a decrease in activity from HBS to VPA was noted for all 
genotypes, as expected (Table 5).  However, this was not statistically significant for any group 
and the effect size was low.  This may indicate that higher than expected doses of VPA are 
required to significantly impact the network.  Additionally, increases in activity were noted for 
both HBS vs. high K+ and VPA vs. high K+, as expected.  However, this trend was not 
significant for transfected or un-transfected cells which may indicate that although these cells 
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respond to high K+, they were not given sufficient time to recover from VPA depression before 
high K+ application.  A1685V cells, however, did show a significant increase in activity from 
HBS to high K+ and VPA to high K+, potentially demonstrating that these mild mutants were 
either more reactive to high K+ following VPA exposure or that they were less reactive to VPA 
than the controls were.  Representative traces illustrate the subtle trends observed as well as the 
variability within single trials (Figure 36). 
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Table 5: Time-to-Fmax P-values, Effect Size, & Trends for Valproic Acid Trials 
 
 
 
 
 
Above: Arrow direction indicates general trend in Time-to-Fmax.  Arrow color indicates the 2 
effect size (grey: no effect, red: small, yellow: medium, green: large).  P-values between 0.01 
and 0.05 shown in bold red.  P-values less than 0.01 shown in bold, italic red.  Significance 
determined by Kruskal-Wallis test. 
 
 
 
 
 105 
Table 6: Time-to-Fmax P-values, Effect Size, & Trends for Induced VPA Trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Above: Arrow direction indicates general trend in Time-to-Fmax.  Arrow color indicates2 effect 
size (grey: no effect, red: small, yellow: medium, green: large).  P-values between 0.01 and 0.05 
shown in bold red.  P-values less than 0.01 shown in bold, italic red.  Significance determined by 
Kruskal-Wallis test. 
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Figure 36: Representative Calcium Traces Following VPA 
 
 
 
Above: Representative calcium imaging traces of 340/380 vs. time following VPA trials. Top: 
Negative control cells, middle: pLL3.74-dsRed cells, bottom: SCN1a A1685V cells.  
Stimulations are indicated by vertical lines. 
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Figure 37: Representative Calcium Traces Following BMI & VPA 
 
 
 
Above: Representative calcium imaging traces of 340/380 vs. time following BMI VPA trials. 
Top: Negative control cells, middle: pLL3.74-dsRed cells, bottom: SCN1a A1685V cells.  
Stimulations are indicated by vertical lines. 
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For CBZ exposure following BMI, all genotypes demonstrated an upward trend in TTF 
for HBS vs. BMI, HBS vs. high K+, BMI vs. high K+, and CBZ vs. high K+ as expected (Table 
8).  Additionally, negative control cells displayed a decrease in TTF when comparing both HBS 
to CBZ and BMI to CBZ.  This is to be expected because, although CBZ is thought to trigger 
seizure activity in GEFS+ patients, it should cause a decrease in network activity in healthy 
patients.  Surprisingly, pLL3.74-dsRed cells exhibit an increased TTF trend for both HBS vs. 
CBZ and BMI vs. CBZ.  The longer TTF when comparing HBS to CBZ could be attributed to 
the significant increase between control and BMI baths leading to higher baseline values going 
into CBZ trials.  If cells become too active during BMI exposure, they may not be able to 
sufficiently recover to below baseline during CBZ exposure.  However, this does not explain the 
increase in TTF from BMI to CBZ.  Finally, A1685V cells demonstrate the expected increase in 
TTF for HBS vs. CBZ but a surprising decrease in TTF from BMI to CBZ.  However, these 
trends are not significant, possibly indicating that our CBZ dose could be increased.  One last 
observation from these trials pertains to A1685V cells.  As all of the drugs in this trial would be 
expected to increase TTF for SCN1a mutants, it is surprising that A1685V does not show any 
significant gains.  This could be caused by a number of things including elevated baseline due to 
a decrease in network inhibition, insufficient drug doses, or cells that are responding maximally 
for electrical stimulation regardless of bath.  Representative traces illustrate the subtle trends 
observed as well as the variability within single trials (Figure 39). 
As for intrinsic CBZ trials, both transfected and un-transfected cells exhibited a decrease 
in activity from HBS to CBZ, as expected (Table 7).  Interestingly, A1685V cells did show an 
increase in TTF when exposed to CBZ following HBS, as expected.  However, this trend was not 
significant, possibly indicating that CBZ doses were too low to impact mutant networks.  As for 
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the comparisons between HBS and High K+, and CBZ and High K+, all genotypes displayed an 
increase in TTF, as expected.  These trend are only significant for negative controls cells, which 
makes sense because they did not demonstrate a significant decrease in TTF following CBZ 
exposure, so they would presumably have a higher baseline going into high K+ exposure 
compared to pLL3.74-dsRed cells.  Neither trend was significant for A1685V cells.  A1685V’s 
combination of minimal response to both CBZ and high K+, both of which should increase 
activity, may point to an elevated baseline for this genotype.  Representative traces illustrate the 
subtle trends observed as well as the variability within single trials (Figure 38). 
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Table 7: Time-to-Fmax P-values, Effect Size, & Trends for Carbamazepine Trials 
 
 
 
 
 
Above: Arrow direction indicates general trend in Time-to-Fmax.  Arrow color indicates 2 effect 
size (grey: no effect, red: small, yellow: medium, green: large).  P-values between 0.01 and 0.05 
shown in bold red.  P-values less than 0.01 shown in bold, italic red. Significance determined by 
Kruskal-Wallis test. 
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Table 8: Time-to-Fmax P-values, Effect Size, & Trends for Induced CBZ Trials 
 
 
 
 
 
Above: Arrow direction indicates general trend in Time-to-Fmax.  Arrow color indicates 2 effect 
size (grey: no effect, red: small, yellow: medium, green: large).  P-values between 0.01 and 0.05 
shown in bold red.  P-values less than 0.01 shown in bold, italic red.  Significance determined by 
Kruskal-Wallis test. 
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Figure 38: Representative Calcium Traces Following CBZ 
 
 
 
Above: Representative calcium imaging traces of 340/380 vs. time following CBZ trials. Top: 
Negative control cells, middle: pLL3.74-dsRed cells, bottom: SCN1a A1685V cells.  
Stimulations are indicated by vertical lines. 
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Figure 39: Representative Calcium Traces Following BMI & CBZ 
 
 
 
Above: Representative calcium traces of 340/380 vs. time following BMI CBZ trials.  Top: 
Negative control cells, middle: pLL3.74-dsRed cells, bottom: SCN1a A1685V cells.  
Stimulations are indicated by vertical lines. 
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4.4 DISCUSSION 
This chapter examined the functional activity of small, genetically modified neuronal networks 
with confined geometry.  To our knowledge, this is the first time that transfected neurons have 
been evaluated as a possible in vitro epilepsy model and also the first time an in vitro epilepsy 
model with confined geometry has been proposed.  
Networks were composed of similar numbers of cells regardless of cell type, indicating 
that transfection and SCN1a mutations had little effect on cell viability (Figure 32).  However, 
our severe mutant (L986F) presented with the fewest number of cells per ring which may be a 
residual effect of this genotype expressing the most extreme mutation possibly causing higher 
rates of cell death and more delicate cells in general.  Additionally, the number of cells per ring 
was slightly lower than the 40-60 cells/ring reported in previous work [92].  The reduction is 
likely due to the modified culture method required to sustain transfected cells. 
Baseline studies demonstrated a variety of calcium transients including spontaneous 
activity, oscillatory behavior, and prolonged responses.  Prolonged responses may be due to 
slower recovery times in transfected cells or may originate from glia which tend have slower 
response times.  It is possible that the SCN1a mutations encourage glia to take a more prominent 
role in network activity. 
In all drug trials, calcium responses were fairly variable between trials for the same 
genotype and same drug making data analysis challenging.  Several factors may be responsible 
for the variation.  One possibility is that some of the large, prolonged responses are coming from 
glia while the briefer responses are neuronal, as our phenotypic analysis showed that cultures 
were composed of a mix of neurons and glia.  Additionally, culture composition between DIV 10 
and 13 may be variable, as was noted in our previous phenotypic analysis.  Most cultures were 
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viable for two to three weeks, with some having noticeable cell death around DIV 14 and other 
lasting until DIV 21.  Additionally, nucleofection is only stable for 12-14 days [70].  The 
majority of calcium imaging experiments were performed between DIV 10 and 13 to allow 
synapses to mature (begins at DIV 7) and before nucleofection stability declined [93, 145, 146].  
However, it is possible that some of the cultures studied began to lose their assigned genotype 
prior to imaging, which could confound results. 
Additionally, much of our interest in confining network geometry lies in the assumption 
that unpatterned substrates allow in vitro cultures to make random intracellular connections that 
vary from coverslip to coverslip but that constrained networks would exhibit consistent behavior.  
However, the majority of microcontact printing work up to this point focused on constraining 
network geometry for logistical purposes such as focusing cells to an electrode, as opposed to 
minimizing variability in network behavior [93, 147, 148].  The wide range of calcium imaging 
responses observed in this chapter suggests that controlling network geometry may not be 
sufficient to reduce in vitro variability on a functional level.  Instead, an additional step of 
segregating cell type may be necessary to better mimic the topological organization of various 
brain regions.  To address this possibility, closer examination of functional activity in patterned 
vs. unpatterned networks is warranted.  Additionally, it may be prudent to examine network 
connectivity prior to and immediately following drug trials using a live cell dye like Lucifer 
Yellow.  This would allow networks to be segregated based on connectivity as opposed to even 
cell body distribution.  It may be that some rings have even cell body distribution but poor 
connectivity resulting in a varied response from a more well-connected network. 
Finally, the drug bath compositions as well as subsequent drug application protocol may 
need to be examined closer- specifically, drug doses and possible drug interactions.  Our drug 
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doses were based on a combination of available literature pertaining to other in vitro work (not 
necessarily neuronal), in vivo data adjusted for blood-brain barrier permeability, and our Trypan 
blue toxicity testing.  However, because few AED trials are done in neurons in vitro, it is 
possible that our “therapeutic” doses were actually sub-therapeutic.  Trypan blue exclusion 
assays illustrated a dose-dependent toxicity to both VPA and CBZ.  However, even our “toxic” 
doses were well below LD50 - the dose at which 50% of cells are killed [149].  Therefore, we 
should be able to increase to our “toxic” dose without serious detrimental effects to our cells.  
Furthermore, BMI-AED interaction could have a potentially confounding effect if BMI is failing 
to thoroughly dissociate uniformly across cultures prior to AED application so rinse times 
between drug applications may need to be reassessed. 
4.5 CONCLUSIONS 
This chapter examined the functional activity of small networks of patterned neurons that have 
been transfected to express epilepsy-related SCN1a mutations.  Ring-shaped networks of 
transfected and un-transfected neurons were successfully created and network activity could be 
assessed using time-lapse calcium imaging.  Additionally, the effect of multiple drugs, including 
AEDs, were quickly and consistently evaluated.  While our goal was to study seizure activity in 
genetically-based seizures, our methods could easily be modified to study chemically or 
electrically induced seizures.  Although this work acts as a proof-of-concept and lays a 
foundation for future studies, there are many improvements yet to be made.  Several of these are 
discussed in the following chapter. 
 117 
5.0  PROJECT SUMMARY 
As a whole, this project demonstrated that a genetically based in vitro epilepsy model could be 
created from wild type and genetically modified hippocampal neurons and that these genetically 
modified cultures could also be geometrically constrained.  To our knowledge, this is the first 
time that a potential in vitro epilepsy model has been created using genetic modifications in 
primary neurons.  Additionally, we believe this is the first time that genetically modified neurons 
have been constrained using microcontact printing.  We have successfully demonstrated SCN1a 
plasmid generation as well as successful transfection and culture of neurons expressing those 
plasmids (Chapter 2, page 25).  Furthermore, we have evaluated the composition of these 
networks and determined subtle compensatory trends that bear further review (Chapter 3, page 
47).  Finally, we have evaluated network functionality and observed subtle but promising trends, 
including responses to AEDs which mimic those seen in vivo (Chapter 4, page 83).  A neuronal 
in vitro epilepsy model of intrinsic, rather than induced, seizure activity would fill a significant 
gap in current epilepsy research.  Additionally, it would meet the NINDS’s suggested guidelines 
for new epilepsy models including cost-effectiveness, propensity for examining disease 
mechanisms, ability to be used in high-throughput testing, and potential for use in personalized 
medicine. 
Moving forward, we would suggest the incorporation of two additional technologies and 
one new direction of investigation that could help build a stronger foundation for our proposed in 
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vitro epilepsy model.  The first would be to add a fluorescent reporter gene to the SCN1a 
plasmids used.  This would quickly allow for definite confirmation of experimental cells 
expressing the SCN1a mutant to rule out the possibility that transfection of the fluorescent 
marker is occurring without the SCN1a plasmid in some cells.  However, the increased plasmid 
size would warrant a re-evaluation of transfection efficiency. 
Secondly, we recommend incorporation of additional methods to confirm other ways to 
constrain network geometry, whether by other microtechniques or by using other patterns.  
Microcontact printing has waned in popularity in the past few years because, although easy, 
inexpensive, and quick, it can be more art than science.  Even a small movement of the hand, 
stamp, or coverslip during stamping can result in poor pattern adherence.  Therefore, more 
substrates than necessary are generally prepped in case a planned coverslip does not display the 
desired network geometry.  While this is a relatively easy fix, if the goal is to create an 
inexpensive in vitro model, an effort should be made to increase pattern repeatability and further 
reduce costs.  One option for doing so would be to explore the use of photosensitive silicone 
where cells can be directly plated onto a biocompatible master.  Additionally, slightly more 
complex patterns may provide additional control over network geometry which may help reduce 
culture-to-culture variability.  
Lastly, we recommend a closer examination of the role glia play in these networks.  Glia 
are known to be essential to proper neuronal development and synapse maturation in vitro [63, 
150].  More recently, glia has been implicated in seizure propagation [151, 152].  Therefore, 
performing a few experiments where cells are cultured using the Banker sandwich method may 
determine whether the large, prolonged calcium responses can be attributed to glia.  Briefly, the 
Banker method involves plating purely neuronal cultures on one coverslip and sandwiching it 
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together with a second coverslip containing mature glia [153].  The proximity of the coverslips 
allows neurons and glia to exchange chemokines, thus ensuring proper synapse development.  
However, the separate coverslips would also allow both purely neuronal and purely glial cultures 
to be examined independently once the coverslips were detached.  Additionally, the reverse 
situation can be employed, where glia are transfected to express SCN1a mutations while neurons 
are not transfected, to examine how Nav1.1 mutations in glia may drive seizure propagation.  
Glia’s role in epilepsy is not widely understood and has only become a topic of interest in recent 
years. 
Overall, we hope that this project can serve as a building block for future research into 
the creation of an in vitro epilepsy model and that it will open up the discussion of in vitro 
“chips” for high throughput testing of AEDs.  One long-term possibility would be to attempt to 
use a chip for personalized medicine.  This appears particularly promising given the recent, 
disease specific induced neuron work by Goldstein and Liu [154, 155].  Goldstein’s group 
demonstrated an ability to create induced pluripotent stem cells (iPSCs) from primary skin 
fibroblasts of Alzheimer’s patients.  The primary fibroblasts could be reprogrammed into iPSCs 
then differentiated into neuronal cultures that displayed normal electro-physical activity.  Even 
more recently, Liu et al used similar techniques to create iPSCs from SMEI patients presenting 
with SCN1a mutations [155].  These iPSCs were differentiated into neurons which displayed 
altered sodium channel current consistent with SMEI. 
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5.1 EPILEPSY ON A CHIP 
The idea of using a fairly non-invasive skin biopsy to generate a personalized cell line that could 
be plated on an inexpensive, high-throughput chip to screen individual or combinations of AEDs 
for a specific patient could truly be a field-changing product.  Specifically, a commercially 
available epilepsy “chip” could be useful in quickly finding the best AED candidates for 
treatment in an individual patient, which would greatly cut down on the time between initial 
diagnosis and controlled seizure status.  Additionally, chips could be used to identify patients 
who are likely to have intractable epilepsies, as their cells would not respond to available AEDs.  
Lastly, inexpensive, disposable chips could be a useful tool for developing new AEDs because 
the mechanisms behind different epilepsies, especially intractable epilepsies, could be examined.  
Once more about the underlying disease mechanism is understood and specific protein targets 
are identified, more effective AEDs could be developed. 
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APPENDIX 
LIST OF ACRONYMS 
AED(s): anti-epileptic drug(s) 
AIS: axon initial segment 
AraC: cytosine arabinoside 
BMI: bicuculline methiodide 
CBZ: carbamazepine 
DAPI: 4’6-diamidino-2-phenylindole (nuclei stain) 
DIV: days in vitro 
DDW: double distilled water 
E18-E19: embryonic day 18-19 
Fmax: maximum fluorescence 
GEFS+: generalized epilepsy with febrile seizures plus, type II 
HBS: HEPES-buffered saline 
High K+: high potassium HBS solution 
iPSC: induced pluripotent stem cells 
LOF: loss-of-function 
MAP2: microtubule-associated protein 1 
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Nav1.1: voltage-gated sodium channel type 1,  subunit (protein) 
PDMS: polydimethylsiloxane 
PLL: poly-L-lysine 
PV: parvalbumin 
ROI: region of interest 
SCN1a: voltage-gated sodium channel type 1,  subunit (gene) 
SMEI: severe myoclonic epilepsy of infancy 
Tau1: microtubule-associated protein Tau1 
TTF: time-to-Fmax 
Vglut1: vesicular glutamate transporter 1 
VPA: valproic acid 
WT: wild type 
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